



Analyzing germline mutation profile pathways by using QIAGEN Ingenuity Pathway Analysis

Cleo Hsi 席佩妤 業務專員Christine Hsiung 熊嘉妮 專案主任Bioinfo@GGA.ASIA



Agenda



- Introduction to QIAGEN Ingenuity Pathway Analysis
- Search in IPA
- Analyzing germline mutation using IPA
 - Data format
 - Data upload and analysis setup
 - Core analysis
- Querying IPA's Knowledge base
 - Custom network construction
 - Contextualization using public data
- Summary





Account: XX@gate.sinica.edu.tw

(xx is your email account)

Password: your password

Download website: https://tinyurl.com/GGAIPA Dataset: https://tinyurl.com/IPAslideshare Client: (IPA Login)






Training account activation code and link by e-mail, please notices your mailbox

Dear Reminder: You have 33 days remaining to activate your QIAGEN IPA trial. Your 14-day trial license activation code is: xUJSRVV2bf2VNIIV. Once activated, your QIAGEN IPA trial will be valid for 14 days. Please be aware that this is an evaluation license and there are limitations on the number of uploads, exports and analyses that can be performed during the trial period. To activate your trial, click here or copy paste this text to a browser https://apps.ingenuity.com/isa/account/protected/signup/ipa? coupon=tpd3U2Yyn1NPSXX4Zt1ZIEhWDjAgqiZK63TVMtzy_Mw-FHZhISQKdPVlgaaJjuTR. The trial can be activated to begin anytime within the next 33 days, and after that the code will expire. We recommend that after you create your account and receive your activation email, you use this installer or copy paste this text to a browser https://analysis.ingenuity.com/pa/installer/select to get started with your QIAGEN IPA trial. We suggest viewing a few tutorials to get you started. You may also want to check out our training videos. If you have any questions, please contact Customer Support at ts-bioinformatics@qiagen.com or by phone at US: +1.650.381.5111 US Toll Free: +1.866.464.3684 or Denmark Toll Free: +45 80 82 0167. Best regards, The QIAGEN Digital Insights Team





(1)	(2) (3)
Create Account	Activate via email Install IPA and Log in
ign-up with Trial Cod	e Join Institution License
fields are required unless otherv	vise indicated.
ogin Information	
Email	₹ <mark>*</mark> **
Trial sign-up code	* If you do not have a trial sign-up code, fill out this form <u>here</u> .
Password	Password strength The password must be at least 12 characters in length and contain at least 1 uppercase letter, 1 lowercase letter, 1 number, special character and no dollar sign(\$) or empty space. Do not use dictionary words, your name, e-mail address, or other personal information that can be easily obtained. Do not use the same password for multiple online accounts.
Verify password	* 12
ame and Contact Informat	ion
First name	*
Last name	*
Institution or Company	Please select an option from autocomplete dropdown







Ingenuity Pathway Analysis

Install IPA on your computer

This installer will enable you to access IPA like other desktop applications on your computer (though still requiring an internet connection). Note: This is all you need to run IPA. It is not necessary to install Java separately from IPA.

Click on the button below to download the installer

IPA for Windows (64-bit) (Installer recommended for your computer)


Other options:

```
IPA for 32-bit Windows
IPA for macOS
```

For more information see this <u>help page</u>.

Note: If you have trouble installing or logging in with the IPA client, please click here for an alternate method to launch IPA.

Looking for more information about IPA? Click here.



Transcriptomics

> Comput Mol Biosci. 2023 Jun;13(2):21-34. doi: 10.4236/cmb.2023.132002. Epub 2023 May 19.

Analysis of Differential Gene Expression and Core Canonical Pathways Involved in the Epithelial to Mesenchymal Transition of Triple Negative Breast Cancer Cells by Ingenuity Pathway Analysis

Elizabeth Cagle ¹, Brent Lake ¹, Anasua Banerjee ¹, Jazmine Cuffee ¹, Narendra Banerjee ¹, Darla Gilmartin ¹, Makaiyah Liverman ¹, Shennel Brown ¹, Erik Armstrong ¹, Santanu Bhattacharya ² ³, Somiranjan Ghosh ⁴, Tanmoy Mandal ⁴, Hirendra Banerjee ¹

Affiliations + expand PMID: 37538932 PMCID: PMC10398793 DOI: 10.4236/cmb.2023.132002

Genomics

> J Neurosurg. 2018 Mar;128(3):911-922. doi: 10.3171/2016.10.JNS161384. Epub 2017 Apr 14.

Genetic landscape of sporadic vestibular schwannoma

Aril Løge Håvik ¹ ² ³, Ove Bruland ², Erling Myrseth ⁴, Hrvoje Miletic ⁵ ⁶ ⁷, Mads Aarhus ⁸, Per-Morten Knappskog ² ³, Morten Lund-Johansen ¹ ⁴ ⁶

Affiliations + expand PMID: 28409725 DOI: 10.3171/2016.10.JNS161384

Abstract

OBJECTIVE Vestibular schwannoma (VS) is a benign tumor with associated morbidities and reduced quality of life. Except for mutations in NF2, the genetic landscape of VS remains to be elucidated.

proteomics

> Hepatol Int. 2023 Jun;17(3):698-708. doi: 10.1007/s12072-022-10473-x. Epub 2023 Jan 18.


Biomarkers of hepatocellular synthesis in patients with decompensated cirrhosis

Berivan Gurbuz [#] ¹, Nurdan Guldiken ¹, Philipp Reuken ², Lei Fu ¹ ³, Katharina Remih ¹, Christian Preisinger ⁴, Radan Brùha ⁵, Martin Leniček ⁶, Jaromir Petrtyl ⁵, Johanna Reissing ¹, Mahmoud Aly ¹¹, ⁷, Malin Fromme ¹, Biaohuan Zhou ¹ ⁸, Isabel Karkossa ⁹, Kristin Schubert ⁹, Martin von Bergen ⁹ ¹⁰ ¹¹, Andreas Stallmach ², Tony Bruns [#] ¹ ², Pavel Strnad [#] ¹²

Affiliations + expand PMID: 36652164 PMCID: PMC10224844 DOI: 10.1007/s12072-022-10473-x Free PMC article

Abstract

Background and aim: Since hepatocytes produce majority of serum proteins, patients with cirrhosis display substantial alterations in the serum proteome. The aim of the current study was to



> Proteomics. 2021 Jun;21(11-12):e2100037. doi: 10.1002/pmic.202100037. Epub 2021 May 31.

訊聯基因數位

Biomarker identification and pathway analysis of rheumatoid arthritis based on metabolomics in combination with ingenuity pathway analysis

Zhuoru He¹, Zhongqiu Liu¹, Lingzhi Gong¹

Affiliations + expand PMID: 33969925 DOI: 10.1002/pmic.202100037

Abstract

Rheumatoid arthritis (RA) is a common autoimmune and inflammatory disease worldwide, but understanding its pathogenesis is still limited. In this study, plasma untargeted metabolomics of a discovery cohort and targeted analysis of a verification cohort were performed by gas chromatograph Ingenuity Pathway Analysis is powered by QUAIGEN knowledge base



Ingenuity Literature Findings

Ingenuity Expert Findings – manually curated Findings from the fulltext with contextual details from top journals

Ingenuity ExpertAssist Findings – automated text Findings that are manually reviewed from abstracts covering a broader range of publications – comprise a small percentage of IPA's findings



Ingenuity Modeled Knowledge

Ingenuity Expert Knowledge – content we model such as canonical pathways, toxicity lists, etc.

Ingenuity-Supported Third-Party Information – content areas include protein-protein, miRNA, biomarker, clinical trial information and others

Ingenuity

Pathway

Analysis

Databases such as COSMIC, Clinical Trials, OMIM, TargetScan, BioGRID, MGD and HumanCyc

A massive, manually curated Knowledge Base updated weekly for the last ~20 years QIAGEN Knowledge Base The Ingenuity Ontology


>12.6 million findings



訊聯基因數位

















Using IPA to Discover Relationships in Experimental Data






Sample to Insight











Fully supported:







IPA can remap orthologous identifiers from the following species:

- Arabidopsis thaliana (Thale cress)
- Bat (*Rhinolophus ferrumequinum*)
- Caenorhabditis elegans
- Cat (domestic, *Felis catus*)
- Chicken (Gallus gallus)
- Chimpanzee (*Pan troglodytes*)
- Chinese hamster (*Cricetulus griseus*, CHO-K1)
- Cow (Bos taurus)
- Crab-eating macaque (*Macaca fascicularis*)
- Dog (Canis lupus familiaris)
- Fruit fly (*Drosophila melanogaster*)
- Golden hamster (*Mesocricetus auratus*)
- Guinea pig, domestic (*Cavia porcellus*)

- Horse (Equus caballus)
- Human (Homo sapiens)
- Mouse (*Mus musculus*)
- Pig (Sus scrofa)
- Rabbit (Oryctolagus cuniculus)
- Rainbow trout (*Oncorhynchus mykiss*)
- Rat (*Rattus norvegicus*)
- Rhesus Monkey (*Macaca mulatta*)
- Saccharomyces cerevisiae
- Schizosaccharomyces pombe
- Western clawed frog (*Xenopus tropicalis*)
- Zebrafish (Danio rerio)





Omics data type

- RNA-seq
- scRNA-seq
- Microarray
- Nanostring
- qPCR
- ChIP-seq
- Proteomics
- Metabolomics
- RNAi
- CRISPR
- WGS/WES etc.

Activation z-score -6.040 5.667	體學種類
Canonical Pathways	t_0 transcriptomics t_60 transcriptomics t_120 transcriptomics t_0 proteomics t_120 proteomics t_120 proteomics t_0 metabolomics t_170 metabolomics
Oxidative Phosphorylation	
Mitochondrial Dysfunction	
Coronavirus Pathogenesis Pathway Neutrophil Extracellular Trap Signaling Pathway Granzyme A Signaling LXR/RXR Activation Fatty Acid β-oxidation 1 Macrophage Alternative Activation Signaling Pathway EIF2 Signaling Xenobiotic Metabolism PXR Signaling Pathway Neurovascular Coupling Signaling Pathway Ethanol Degradation IV Ethanol Degradation II Oxidative Ethanol Degradation III MicroRNA Biogenesis Signaling Pathway Superpathway of Citrulline Metabolism Superpathway of Cholesterol Biosynthesis Glutaryl-CoA Degradation IGF-1 Signaling Xenobiotic Metabolism AHR Signaling Pathway RHOA Signaling Xenobiotic Metabolism General Signaling Pathway Glutathione-mediated Detoxification Sirtuin Signaling Pathway Ribonucleotide Reductase Signaling Pathway CREB Signaling in Neurons Salvage Pathways of Pyrimidine Ribonucleotides	

路

徑名稱






With dataset	Without dataset
 Find connections in your data 	 Search and explore the QIAGEN Knowledge Base
 Identify novel biomarkers 	 Test hypothesis in silico
 Uncover key targets and regulators 	 Identify degree of novelty in a hypothesis
 Discover novel disease mechanisms 	
 Compare across experiments 	



IPA with OmicSoft Land Explorer






IPA Gene View :OmicSoft Land Explorer



•




TCGA-B38-G33








- Through DiseaseState filter, to observe the expression difference of EGFR gene in cancer type in TCGA
- Select a specific experimental group to view more detailed information.








TCGA_B38_GC33





Diseases regulation





		Dataset and analysis se					arch		ざ 訊聯基因數位
								2	
	File Edit	View Window Help						2	Provide Feedback Support Gene Chen Close IPA
		Genes and Chemicals	Diseases a	nd Functions	Pathways and Lists Dat	asets and Analyses			
	Create N	lew lung cancer					Sea	Advanced Search	QIAGEN Land Explorer QIAGEN
	Search Resi	ults							- 0 ×
	Search Results								
	Showing fire	rst 5000 results out of 33129 in 18888m	ns for query [l	lung cancer]			Libraries > OmicSc	oft > SingleCellLand > SingleCellHumanUmi > Analyses	
	FolderTu						/	carcinoma (LUAD);lung squamous cell carcinoma (LUSC) [lung] 1869	
	Folder Type						the rang duent		
		<u>ataset (17090)</u> aalysis (16031)					0		
	4 : <u>va</u>	arianLossGain (8)					Case/Control Diff	erences	
		*					Key	Case Control	
								1 0;10;11;12;13;14;15;16;17;18;19;2;20;3;4;5;6;7;8;9	
	Open	Add to Comparison Customi:	ize Table	Crea	2024/ 2024/ (1/125)	~ « »	cluster 1		
	Name			Туре		case.diseasesta	clustercelltype	T cell alveolar epithelial cell;B cell;cytotoxic T cell;endothelial cell;epithelial cell;fibroblast;macrophage;mast cell;monocyte;myeloid cell;N	K cell;T cell;unassigned cell
				analysis	2024/03/04 23:36:43	case.uiseaseste			
	colon cancer-			dataset	2024/03/04 23:33:24		Comparison Cont	text	
		cancer [breast] 1293		analysis	2024/01/12 09:20:15	breast cancer	companyor com		
	263- normal (control [bladder;bone;bone marrow;brain		analysis	2024/01/12 09:19:07	normal control	cellmarkers	CD235A-	
	4631- breast	cancer [peripheral blood] 4630		analysis	2024/01/12 09:17:53	breast cancer	celltype	lung cell	
	4938- breast	cancer [breast] 4937		analysis	2024/01/12 09:17:39	breast cancer	comparisoncateg	ory Cluster vs Others	
		cancer [breast] 5222		analysis	2024/01/12 09:17:22	breast cancer	comparisoncontra	ast T cell (cluster) vs others	
5	-	denocarcinoma (LUAD);lung squamous c		analysis	2024/01/12 09:17:15	lung adenocarci	diseasestate	lung adenocarcinoma (LUAD);lung squamous cell carcinoma (LUSC)	
3		I control;pulmonary fibrosis [lung] 2445		analysis	2024/01/12 09:16:59	normal control;p	ethnicity	Caucasian	
		ocellular carcinoma (LIHC);intrahepatic ch	-		2024/01/12 09:16:30	hepatocellular ca	gender	female;male	
		control [testis] 313		analysis	2024/01/12 09:16:24	normal control	organism	human	
		l control [fetal lung] 1239 cancer [breast] 3917		analysis analysis	2024/01/12 09:16:13 2024/01/12 09:15:24	normal control breast cancer	platformname	NGS.Illumina.NextSeq500	
		concer [breast] 3917 c obstructive pulmonary disease (COPD);		analysis	2024/01/12 09:14:00	chronic obstruct	smokingstatus	ex-smoker;NA	
		ctal cancer [colonrectum] 8969		analysis	2024/01/12 08:40:25	colorectal cancer	tissue		
		ctal cancer [colonrectum] 8974		analysis	2024/01/12 08:40:15	colorectal cancer	tnmstage	pN0;pT1a;pN0;pT2a;pN1;pT1b;pNX;pT2a	
		eloid leukemia (LAML) [bone marrow] NA		analysis	2024/01/09 02:17:06	acute myeloid le			
	1- acute mye	eloid leukemia (LAML) [bone marrow] NA	A 213	analysis	2024/01/09 02:16:46	acute myeloid le	All Experiment Me	etadata	
	1- breast can	ncer [breast;lymph node;peripheral blood;] 0	analysis	2024/01/09 02:13:03	breast cancer			
	1- breast can	ncer [breast] 68		analysis	2024/01/09 02:12:49	breast cancer	case.cellmarkers	CD235A-	
	1- breast can	ncer [peripheral blood] NA 8		analysis	2024/01/09 02:12:37	breast cancer	case.celltype	lung cell	
		cinoma [breast] estradiol;ethanol 0		analysis	2024/01/09 02:12:21	breast carcinoma	case.cluster	1	
		cinoma [breast] estradiol;ethanol 4		analysis	2024/01/09 02:12:05	breast carcinoma	case.clustercelltyp		
		cancer [ovary] NA 4		analysis	2024/01/09 02:09:17	germ cell cancer	case.diseasestate		
		ar cell sarcoma (CCSK) [kidney] NA 14		analysis	2024/01/09 02:07:58	kidney clear cell	case.ethnicity	Caucasian	
		abdoid cancer [kidney] Transfection_BAF4 I acute lymphocytic leukemia [hematopoi		analysis analysis	2024/01/09 02:07:40 2024/01/09 02:02:21	kidney rhabdoid childhood acute	case.gender	female;male	
		ial cancer;endometrial squamous cell carc		-	2024/01/09 02:02:21	endometrial can	case.samplemater		
—	. ensemeth						case.smokingstatu	us ex-smoker;NA	





Volcano plot


	ect a set of molecules from your datas ated molecules, and not more than 800 dictions.					Note t	hat fold cha	nges are co	inverted to log2 for	them with their name charting purposes.		
et Cutoffs						35	NR4A1	CLC	F1 MIR22HG		ZNF397	
ataset Column	Measurement Value Type	Range	Cutoff					CD55	• LMO7			
og2FoldChange	Expr Log Ratio	-5.3512 to 4.1489	-0.99 Down	0.8	Up	30 5 25	ſ	DUSPS	LMO7	NA	PEPLONPLAS	NFE2
value	Expr p-value	0.0 to 0.9999				Pvalue [-log10]		OSB GR3	1.32	14	THAP2	
djustedPValue	Expr p-value	0.0 to 0.9999	0.01			onlave 15	•	UK3	1	. And	FRMD4A	
umeratorValue	Expr Intensity/RPKM/FPKM/Counts					10					•	RP11_214K324
enominatorValue	Expr Intensity/RPKM/FPKM/Counts	1.6911 to 19.4031				0			· All		° 2.	
kprOther	Expr Other	0.0 to 1.0	Dowr		Up		-6 -5	-4	-3 -2 -1 Log2Fo	0 1 oldChange	2 3	4 5
						Log2FoldC	hange	Pvalue	[-log10]	V Update Axes	Clear Mc	olecule Names
Advanced	Recalculate	1410 analysis-r	eady molecules (7	48 Down ar	nd 662 Up)							
Preview Dataset	100- disease control [airway epithel	ium] 26883										





Easy to find relationship summary

BBSome Signa...







Easy to find relationship summary

HNRNPK

mRNA processing

(TP53)

(ATF2)


,

(ELK1)

Transcription

growth Differentiation Apoptosis Survival

Cell



NFATC3

NFATC1

,

(JUN)

Cell

TRB (Click to see complete details) Interaction Network

Canonical Pathway membership

Hematopolesis from Pluripotent Stem Cells, TEC Kinase Signaling, CTLA4 Signaling in Cytotoxic T Lymphocytes, T Helper Cell Differentiation, CD28 Signaling in T Helper Cells, Chaperone Mediated Autophagy Signaling Pathway, T Cell Receptor Signaling, Th1 Pathway, Th2 Pathway, Phospholipase C Signaling, Type I Diabetes Mellitus Signaling, Altered T Cell and B Cell Signaling in Rheumatoid Arthritis. NUR77 Signaling in T Lymphocytes. PKC0 Signaling in T Lymphocytes, Allograft Rejection Signaling, Autoimmune Thyroid Disease Signaling, Graft-versus-Host Disease Signaling, Regulation of IL-2 Expression in Activated and Anergic T Lymphocytes, Role of NFAT in Regulation of the Immune Response, G Protein Signaling Mediated by Tubby, Systemic Lupus immunotherapy pathway, SAPKUNN signature Communication between Innate and Adaptive Immune Show more

Top Findings

Binds: PTCRA, DVL2, B2M, CANX, CD247, TRA, CD3E, Pvr. CTCF, RUNX1

Disease:

neoplasia, sepsis, cancer, adenoma formation, epithelial neoplasia, benign neoplasia, Sézary syndrome, pituitary gland adenoma, head and neck neuroendocrine neoplasia, adult T-cell leukemia/lymphoma

Regulates:

TNF, IFNG, ERK1/2, NR4A1, BCL2, BAX, P38 MAPK, RELA, IL10, NFKBIA

Role in cell:


expression in, growth, proliferation, cell death, apoptosis, activation in, cell viability, production in, activation, binding in

Regulated by:

NOS2, lipopolysaccharide, T lymphocytes, cyclosporin A, ETS1, TRAT1, NOTCH1, 26S proteasome,












Upstream Regulators Causal	Networks					
Add To My Pathway Add	To My List Display as N	etwork Acti	vity Plot Custo	mize Table Mechar	nistic Networks 🛛 🔒 釄 🔅	
Upstream R T × Expr Log R	atio T × Molecule Type T ×	Predicted A	▼ × 🗸 Activatio	T × B-H correct	■ × Target Molec ▼ × Mechanis	tic T ×
AGO2	translation regulator	Activated	2.365	2.59E-10	↑let-7a-5p (andall 10	
SSB	enzyme	Activated	2.000	8.96E-05	♣let-7a-5p (andall 4	
PARN	enzyme		1.982	2.73E-07	♣let-7a-5p (andall 4	
INSR	kinase		1.475	4.45E-03	↑miR-411-3p (anall 5	
5-fluorouracil	chemical drug		1.452	7.63E-03		
IGF1R	transmembrane recepto	r	1.387	4.98E-04	↑miR-411-3p (anall 5	
rimonabant	chemical drug		1.265	3.57E-11	↑miR-151-3p (aall 10	
docetaxel	chemical drug		1.236	2.03E-05	♣let-7a-5p (andall 5	
EPHB6	kinase		1.213	8.38E-07	↑let-7a-5p (andall 5	
DAZL	translation regulator		1.119	1.98E-06	↑let-7a-5p (andall 4	
DICER1	enzyme		1.111	2.98E-06	✦let-7a-5p (andall 7	
calcifediol	chemical - endogenous.		0.456	3.91E-10	✦let-7a-5p (andall 6	
Gnasas1	other		0.000	5.27E-07	✦let-7a-5p (andall 5	
CG	complex		0.000	3.56E-03	↑let-7a-5p (andall 5	
nydrogen peroxide	chemical - endogenous.		-0.198	6.23E-05	↑let-7a-5p (andall 7	
ALOX5	enzyme		-0.215	1.86E-08	↑let-7a-5p (andall 9	
PAX3-FOXO1	fusion gene/product		-0.757	3.50E-06	✦let-7a-5p (andall 7	
PPARA	ligand-dependent nucl		-1.342	2.05E-04	↑let-7a-5p (andall 6	
acetaminophen	chemical drug		-1.539	1.08E-09	↑let-7a-5p (andall 9	
monocrotaline	chemical toxicant		-1.982	2.40E-05	↑let-7a-5p (andall 4	
NORAD	other			7.53E-03	↑miR-125a-3p (all 2	
DGCR8	enzyme			9.70E-03	✦let-7a-5p (andall 2	
Gulo	enzyme			1.49E-05	♣let-7a-5p (andall 3	
MTDH	transcription regulator			6.81E-03	ImiR-16-5p (anall 3	
resolvin D1	chemical - endogenous.			8.93E-03	↑miR-21-5p (anall 2	
GFI1	transcription regulator			5.43E-03	↑miR-21-5p (anall 3	











Explore eight new and two updated pathways New Ingenuity signaling pathways

- BBSome Signaling Pathway
- Folate Signaling Pathway
- HEY1 Signaling Pathway
- IL-27 Signaling Pathway
- Sleep NREM Signaling Pathway
- Sleep REM Signaling Pathway
- UFMylation Signaling Pathway
- WNT/SHH Axonal Guidance Signaling Pathway

Existing pathways updated to include an activity pattern

- Eicosanoid Signaling Pathway
- Gap Junction Signaling Pathway





Addition of >168,000 new findings (bringing the total in IPA to over 13.1 million)

>143,000 Expert findings (from literature curation)

- >12,600 protein-protein interaction findings from BioGrid
- >4,700 cancer mutation findings from ClinVar
- >3,900 protein-protein interaction findings from IntAct
- >1,700 drug-to-disease findings from ClinicalTrials.gov
- >1,200 target-to-disease findings from ClinicalTrials.gov
- >600 gene-to-disease findings from the Online Inheritance in Man (OMIM)
- >300 findings from Clinical Genome Resource (ClinGen)
- >100 Gene Ontology findings
- >50 newly mappable chemicals





149,657 expression datasets (2,436 added)

.....

Land	Repository	Datasets Q3 2023	Datasets Q4 2023	Increase
	HumanDisease	34,317	35,112	795
DiseaseLand	MouseDisease	26,164	26,584	420
	RatDisease	9,287	9,287	
	LINCS	28,234	28,234	
	OncoHuman (Formerly OncoGEO)	20,152	21,373	1,221
	OncoMouse	1,054	1,054	
	TCGA	4,438	4,438	
OncoLand	MetastaticCancer	81	81	
OncoLand	Hematology	4,267	4,267	
	Pediatrics	444	444	
	ENCODE RNA Binding	486	486	
	ClinicalProteomicTumor	254	254	
	SingleCellHuman	194	194	
	SingleCellHumanUmi	11,049	11,049	
Single Cell Land	SingleCellHumanUmiLite	603	603	
	SingleCellHumanHCL	1,469	1,469	
	SingleCellMouse	81	81	
	SingleCellMouseUmi	3,220	3,220	
	SingleCellMouseUmiLite	115	115	
Normal Cells and Tissues	Human Tissues (GTEx)	1,312	1,312	





Comprehensive germline genomic profiles of children, adolescents and young adults with solid tumors

Hand on Case Study






In a study of 1,507 C-AYA patients with solid tumors, 12% had pathogenic variants in known cancer-predisposing genes (KCPG), and 61% had such variants in non-KCPG genes like PRKN, SMARCAL1, and SMAD7. Pathway analysis pinpointed p53 as a key network. Drug-target analysis revealed that 1/3 of patients with germline P/LP variants had druggable alterations, with over half from non-KCPG genes, emphasizing the significance of considering candidate genes for targeted therapies.

Akhavanfard, S., Padmanabhan, R., Yehia, L. *et al.* Comprehensive germline genomic profiles of children, adolescents and young adults with solid tumors. *Nat Commun* **11**, 2206 (2020). https://doi.org/10.1038/s41467-020-16067-1

Source	CCF/PCGP/SJLIFE							
Age group	Children	Adolescent	Young adult	Unknown	Total			
Female/Male	600/582	67/97	5/15	14/13ª	686/707			
Mean age of onset	6.1 ± 4.5	16.9 ± 1.3	22±2.4	NA	7.6 ± 5.8			
All solid tumors (1507)	1182	164	20	141	1507			
Central nervous system (323)	266	23	2	32	323			
Wilms tumor (207)	189	2	1	15	207			
Neuroblastoma (190)	158	2	1	29	190			
Rhabdomyosarcoma (134)	114	14	1	5	134			
Osteosarcoma (129)	78	42	5	4	129			
Retinoblastoma (98)	84			14	98			
Ewing's sarcoma (95)	58	27	5	5	95			
Soft tissue sarcoma (93)	69	17	3	4	93			
High-grade glioma (80)	63	8		9	80			
Germ cell tumor (74)	57	11	1	5	74			
Low-grade glioma (24)	8	1		15	24			
Adrenocortical carcinoma (22)	20	1		1	22			
Carcinoma (14)	7	7			14			
Giant cell tumor (3)	0	3			3			
Renal cell carcinoma (3)	2		1		3			
Low malignant potential renal tumors (2)	2				2			
Basal cell carcinoma (1)	1				1			
Paraganglioma (1)		1			1			
Other solid tumor (10)	3	4		3	10			
Non-malignant tumor (4)	3	1			4			

CCF Cleveland Clinic Foundation, PCGP Pediatric Cancer Genome Project, SILIFE, St. Jude Life Cohort. a Gender data were not available for all the patients in this group


Fig. 2 Distribution of germline pathogenic/likely pathogenic (P/LP) mutations in children, adolescents, and young adults (C-AYA) with solid tumors





Pathway analysis results





ig. 4 Pathway analysis of altered genes with germline pathogenic/likely pathogenic (P/LP) variants in children, adolescents, and young adults C-AYA) with solid tumors. a Affected pathways based on altered genes with P/LP germline variants. Top panel: only known cancer-predisposing genes KCPG), lower panel: a combination of all KCPGs and candidate genes. Size of the circles increases as the fraction affected increases. **b** Genes mutated in 'P53 (top panel) and RAS-RTK (lower panel) pathways, and the number of patients affected in our cohort. Red font: tumor suppressor genes; blue font: ncogenes. **c** Top network, predicted by Ingenuity Pathway Analysis (IPA), based on all the KCPG (green color) and candidate genes (salmon color) with at sast four P/LP variants in our C-AYA patients with solid tumors (right-tailed Fisher's exact test $P = 1 \times 10^{-42}$). **d** Eukaryotic Translation Initiation Factor 4 iamma 1 (EIF4G1, B-H corrected $P = 1.39 \times 10^{-3}$) and I kappa b kinase (IkB kinase, B-H corrected $P = 1.39 \times 10^{-3}$) predicted to be the top upstream -egulators/causal network based on our IPA analysis. Right-tailed Fisher's exact test was used, and Benjamini-Hochberg (B-H) *P* value correction erformed to reduce the false discovery rate (FDR).

123456789 >





	Observati	on 1	Observation 2			
				1		
Molecule Identifier	case group1 vs control Log2FoldChange	case group1 vs control PValue	case group2 vs control Log2FoldChange	case group2 vs control PValue		
MARC1	0.0329	0.9119	-0.0845	0.8191		
MARCH1	-0.6943	0.1086	0.8869	0.1408		
SEPT1	-0.302	0.5747	-0.6987	0.3448		
DEC1	-0.0312	0.9897	-2.999	0.4243		
A1CF	0.7462	0.408	0.3415	0.7623		
A2M	0.5054	0.3388	-1.2587	0.0047		
A2MP1	0.709	0.5078	-0.5113	0.7604		
A3GALT2	0.9241	0.8273	2.3056	0.4726		
AAAS	0.0373	0.8668	0.0646	0.716		
AACS	-0.0859	0.7724	-0.5843	0.1295		
ABAT	-0.114	0.854	-0.4218	0.4668		

Significance (optional)

Log2, ratio, fold change, etc. (recommended)

Common identifier types

IDs (required)

Proteomics: UniProt, GenPept (Entrez or HUGO)

Metabolomics: KEGG, CAS registry, HMDB, PubChem.

- Accepted file formats RNA/scRNA-seq: Ensembl, Gene symbols (Entrez or Hugo)
 - .txt (tab-delimited text files)
 - .xls, .xlsx, .csv (Excel tables) ٠
 - .diff (Cuffdiff output)

IDs are the only required column

Change values are needed to calculate activity predictions

Sample to Insight





Get more complete mapping during dataset upload!

Vendor IDs	Gene	Protein	Transcript	microRNA	SNP	Chemical
Affymetrix (na36)	Entrez Gene (2020/10)	GenPept	Ensembl (101)	miRBase (mature)	Affy SNP IDs	CAS Registry Number
Agilent	GenBank (239)	International Protein Index (IPI)	RefSeq (human \ mouse)	miRBase (stemloop)	dbSNP	HMDB
Life Tech (ABI)	Symbol-human (HUGO/ HGNC, EG)	UniProt/ Swiss-Prot Accession (2020_03)	UCSC (hg18)			KEGG
Codelink	Symbol- mouse (EG)		UCSC (hg19)			PubChem CID
Illumina	Symbol- rat (EG)		UCSC (hg38)			
Ingenuity	GI Number					
	UniGene					





Gene symbol

		4	
	А	В	С
1	Hugo_Sym	IVA_Predic	ction
2	BRCA2	2	
3	GJB2	2	
4	TP53	2	
5	ABCA3	1	
6	ABCA3	2	
7	ABCC6	1	
8	ACADS	2	
9	ACADS	2	
10	ACSF3	1	
11	AGBL5	2	
12	AGRN	1	
13	AIPL1	2	
14	ALDOB	2	
15	ALG13	1	
16	APOC3	2	
17	AQP5	2	
18	ARMC4	2	
19	ATP8B1	2 2 2	
20	BBS1	2	
21	BBS12	2	
22	BLOC1S3	1	
23	С9	2	
24	CAPN1	2	
25	CD36		
26	CD96	2	
27	CDHR1	1	
28	CDKALI	2	
29	CHD7	1	
30	CIB2	2	
31	CLCN1	2	
32	CLN8	1	
33	CLPB	1	
34	CLRN1	2	
4		⊤作実1	A

ACMG value

Allowable values are:

- -2 benign
- -1 likely benign
- 0 uncertain significance
- l likely pathogenic
- 2 pathogenic

		GWAS rs id
	А	
1	Risk loci	
2	rs6012915	
3	rs6095946	
4	rs6091189	
5	rs6014965	
6	rs1741640	
7	rs9983528	
8	rs4616575	1
9	rs130651	2
10	rs5751474	3
11	rs34256596	4
12	rs9614460	5
13	rs9330814	6
14	rs2732875	7
15	rs174537	8
16	rs10751097	9
17	rs11236187	1(
18	rs117042741	11
19	rs55864876	12
20	rs2155065	13
21	rs3087967	14
22	rs497916	1!
23	rs10774214	16
24	rs3217810	1
25	rs3217874	18
26	rs10849432	
27	rs10849434	
28	rs77969132	
29	rs2730985	

Multi	ole ID colum	nns
	l.	
	/	

4	A	В
1	Risk loci	Mapped gene
2	rs6012915	LINC01271
3	rs6095946	COX6CP2
4	rs6091189	RIPOR3
5	rs6014965	BMP7
6	rs1741640	LAMA5
7	rs9983528	PCNT
8	rs4616575	ZNRF3
9	rs130651	PDGFB
10	rs5751474	SCUBE1
11	rs34256596	LINC01639
12	rs9614460	SMC1B
13	rs9330814	WNT7B
14	rs2732875	SHROOM2
15	rs174537	MYRF
16	rs10751097	ANO1
17	rs11236187	POLD3
18	rs117042741	XRRA1



Upload dataset



e Edit View Window Help				Provide Feedback
G nes and Cher Create New	micals	Diseases and Functions Pathways and Lists Datasets and An	Advanced Search	
Filter dene nam	nes/symł	ols/IDs or chemical/drug names here	Search Search	
Core Analysis	×			
Comparison Analysis				
Biomarker Filter	esh			
Biomarker Comparison Analysis				
MicroRNA Target Filter BioProfiler	ation			
IsoProfiler				
My Pathway		Quick Start	×	
Path Designer		News		
Filter Dataset				
Upload Dataset		Getting started		
Advanced Search				
Project		Exploring large public data resources through IPA		
Compare		anough in A	Carlos Contraction of the Contra	
Import Pathway		Exploring IPA knowledge		
		Analyzing mRNA or proteomics data	The product of the second of t	
		Analyzing microRNA data		
			News	
		Analyzing phosphoproteomics data	 Starting in Jan 2024, analyses >10 years old will be eligible for <u>automatic deletion</u>. 	
		Analyzing genetic gain/loss data	Sign up for an <u>IPA training webinar!</u>	
		······	Check out our NEW <u>1-minute IPA promo video</u> .	
		Analyzing metabolomics data	Check out the single cell expression tutorial.	
			Read and watch our <u>gene expression tutorial</u> with embedded videos.	
		Case studies and Support webinars	The IPA downtime for the upcoming IPA 2023 Winter Release has been scheduled for:	
		Ten halp articles and EAOs	Pacific Standard Time: Friday, December 15, 5 p.m. through Sunday, December 17, 12 p.m. PST (Noon).	
		Top help articles and FAQs	Central European Time: Saturday, December 16, 02:00 through Sunday, December 17, 21:00. Japan Standard Time: Saturday, December 16, 10:00 through Monday, December 18, 05:00.	
		Contacting Support	China CST (Beijing): Saturday, Saturday, December 16, 23:00 through Monday, December 18, 18:00.	
			If you are new to IPA or taking a trial please see: IPA Trial Resources.	
		Shortcuts	Pave your way to greatness using advanced pathway analysis: Learn more.	
			· Read our <u>news</u> and sign up for our newsletter.	
			Search Google Scholar for <u>publications that cite IPA</u> .	
			· See how the IPA team is using Machine Learning in a new paper.	
			Don't Show at Startup	





– 🗗 🗙

Dataset Upload - Nature_comm_2020_germline_variants_ACMG.xlsx

1. Select File Format:	Flexible Format V
2. Contains Column Header:	● Yes ◯ No
3. Select Identifier Type:	Please assign at least one column below as "ID", and assign the identifier type(s).
	Assign additional columns as ID to improve mapping coverage if desired.
4. Array platform used for experiments:	Not specified/applicable V Select relevant array platform as a reference set for data analysis.
5. Use the dropdown menus to specify th	ne column names that contain identifiers and observations. For observations, select the appropriate measurement value type.

ID/Observation Name	ID ~	Observatio V		
ID/Observation Name	ID 🗸	Observatio V		
ib) observation rame				
		Expr Fold C 🗸		
Measurement/Annotation				
Measurementy Annotation	Gene Symb 🗸			
1	Hugo_Symbol	IVA_Prediction		
2	BRCA2	2		
3	GJB2	2		
4	TP53	2		
5	ABCA3	1		
6	ABCA3	2		
7	ABCC6	1		
	ACADS	2	Variant ACMG Classification - expected values: [-2, 2]	
9	ACADS	2	Variant ACIVIG Classification - expected values: [-2, 2]	
10	ACSF3	1		
11	AGBL5	2		
12	AGRN	1		
13	AIPL1	2		
14	ALDOB	2		
15	ALG13	1		
16	APOC3	2		
17	AQP5	2		
18	ARMC4	2		
	ATP8B1	2		
20	BBS1	2		
	BBS12	2		
	BLOC153	1		
23	C9	2		
	CAPN1	2		
25	CD36	2		

Help

Cancel

Save



									*	≘⊓ ਸ਼% ਵਿ ⊏⊐ ਥ	∎Ь / →
Consecut Char	-il-	Diseases and Functions	Pathways and Lists	Datasets and Analyses							
Create New				s	earch Advanced Search					QIAGEN Land Explo	orer QIAGEN
Core Analysis											
Comparison Analysis	r	_variants_ACMG									- 0 ×
Biomarker Filter	ermline	variants_ACMG									
Biomarker Comparison Analysis	All	Ds (99) Metadata									
MicroRNA Target Filter											
BioProfiler	y List	Create Dataset Custo	omize Table							Symbol ABCA3 - WFS1 (1/1)	\sim \ll \gg
IsoProfiler	ID		Flags	🗙 👝 Symbol	T 🗵 Entrez Gene I	Name X	Location	X Type(s)		× Drug(s)	X
My Pathway	ABCA3		D	ABCA3*		assette subfamily A member 3		transporter		Diug(s)	
Path Designer	ABCA3		D	ABCA3*		assette subfamily A member 3		transporter			_
Filter Dataset	ABCC6		2	ABCC6	-	assette subfamily C member 6		transporter			
Upload Dataset	ACADS		D	ACADS*		ydrogenase short chain	Cytoplasm	enzyme			
	ACADS		D	ACADS*		ydrogenase short chain	Cytoplasm	enzyme			
Advanced Search	ACSF3			ACSF3	acyl-CoA synth	hetase family member 3	Cytoplasm	enzyme			
Project	AGBL5			AGBL5	AGBL carboxy	peptidase 5	Cytoplasm	peptidase			
Compare	AGRN			AGRN	agrin		Plasma Membrane	other			
Import Pathway	AIPL1			AIPL1	aryl hydrocarb	oon receptor interacting prot	Nucleus	other			
2.000	ALDOB			ALDOB	aldolase, fructo	tose-bisphosphate B	Cytoplasm	enzyme			
1.000	ALG13			ALG13	ALG13 UDP-N	I-acetylglucosaminyltransfer	Cytoplasm	enzyme			
2.000	APOC3			APOC3	apolipoproteir	n C3	Extracellular Space	transporter		volanesorsen	
2.000	AQP5			AQP5	aquaporin 5		Plasma Membrane	transporter	,		
2.000	ATP8B			ATP8B1		pholipid transporting 8B1	Plasma Membrane	transporter			
2.000	BBS1			BBS1	Bardet-Biedl sy		Extracellular Space	other			
2.000	BBS12			BBS12	Bardet-Biedl sy		Extracellular Space	other			
1.000	BLOC1			BLOC1S3	_		Cytoplasm	transporter			
2.000	BRCA2			BRCA2		epair associated	Nucleus		on regulator		
2.000	C9			C9	complement C	.9	Extracellular Space	other			
2.000	CAPN1			CAPN1	calpain 1		Cytoplasm	peptidase		alicapistat, BLD-2660	
2.000	CD36			CD36 CD96	CD36 molecule		Plasma Membrane		orane receptor	VT1021, zeaxanthin	
2.000	CD96 CDHR1			CD46 CDHR1	CD96 molecule	e ed family member 1	Plasma Membrane Plasma Membrane	other other		GSK6097608	
2.000	CDKAL			CDKAL1		bry subunit associated protei					
1.000	CHD7	I		CHD7	-	in helicase DNA binding prot		enzyme enzyme			
2.000	CIB2			CIB2		ntegrin binding family memb		kinase			
2.000	ICK			CILK1		ssociated kinase 1	Cytoplasm	kinase			
2.000	CLCN1			CLCN1	-	ge-gated channel 1	Plasma Membrane	ion channe			
1.000	CLN8			CLN8		embrane ER and ERGIC protein		other			
1.000	CLPB			CLPB			Nucleus		on regulator		
2.000				CLRN1	clarin 1	55 5	Diasma Membrane	other			

0/99 Flags:

"D" - Duplicates. Gene/Protein/Chemical identifiers marked with an asterisk indicate that multiple identifiers in the dataset file map to a single gene/chemical in the Global Molecular Network.

"O" - Override molecules. Gene/Protein/Chemical identifiers marked as "Override" are displayed with italic text.

"A" - Gene/Protein/Chemical ID marked as Absent. The gene/protein/chemical will not be used as a focus molecule or appear in networks unless you also explicitly override this flag with the Override column.





	- i						1.11	
Genes a	and Chemicals Diseases and F	unctions Pathways and Lists D		dvanced Search 🔯			QIAGEN Land Exp	plorer
notated Dataset: Nature_com	m_2020_germline_variants_ACMG	3						- (
eview Dataset Nature_comm	n_2020_germline_variants_ACMG	Ĵ						
	Add To My List Create Datas						Symbol ABCA3 - WFS1 (1/1)	~ « [
ariant ACMG Classification	× ID	Flags	🗶 🔟 Symbol	T X Entrez Gene Name	Location	X Type(s)	× Drug(s)	
	ABCA3	Plags	APCA2+	ATD his dire south subfacily A south			Drug(s)	
000	ABCA3	D	Create Core Analysis		X	transporter		
000		D	Colorted Detects No. 1		0	transporter		
00	ABCC6 ACADS	D	Selected Dataset: Nature_comm_2020_g	ermline_variants_ACMG	0	transporter		
000	ACADS	D	Based on this dataset, which Core Ana	ysis type would you like to run?		enzyme		
000	ACSF3	b	Mariant Effects Analysis and			enzyme		
000	AGBL5		Variant Effects Analysis 🗸			enzyme peptidase		
00	AGRN		On which measurement type would yo	u like to base the analysis?		other		
00	AIPL1			-		other		
000	ALDOB			is measurement will be used to calculate				
000	ALG13			rectionality (z-scores) in the analysis and will be splayed in color on pathways and networks. If you		enzyme enzyme		
000	APOC3			noose a non-directional measurement (e.g. p-value)		transporter	volanesorsen	
000	AQP5			en z-scores will not be calculated.		transporter	volanesorsen	
000	ATP8B1					transporter		
000	BBS1					other		
000	BBS12					other		
000	BLOC153					transporter		
000	BRCA2					transcription regulator		
000	C9					other		
000	CAPN1					peptidase	alicapistat, BLD-2660	
000	CD36					transmembrane receptor	VT1021, zeaxanthin	
000	CD96					other	G5K6097608	
000	CDHR1					other		
000	CDKAL1					enzyme		
000	CHD7		Back		Next	enzyme		
000	CIB2		CIB2	calcium and integrin binding family memb	Cvtoplasm	kinase		
000	ICK		CILK1	ciliogenesis associated kinase 1	Cytoplasm	kinase		
000	CLCN1		CLCN1	chloride voltage-gated channel 1	Plasma Membrane	ion channel		
000	CLN8		CLN8	CLN8 transmembrane ER and ERGIC prote		other		
.000	CLPB		CLPB	ClpB family mitochondrial disaggregase	Nucleus	transcription regulator		
000	CLIDN1		CLRN1	clarin 1	Diasma Membrane	other		

^{0/99} Flags:

"D" - Duplicates. Gene/Protein/Chemical identifiers marked with an asterisk indicate that multiple identifiers in the dataset file map to a single gene/chemical in the Global Molecular Network.

"O" - Override molecules. Gene/Protein/Chemical identifiers marked as "Override" are displayed with italic text.

"A" - Gene/Protein/Chemical ID marked as Absent. The gene/protein/chemical will not be used as a focus molecule or appear in networks unless you also explicitly override this flag with the Override column.





– 🗇 🗙

Dataset Upload - Nature_comm_2020_germline_variants_ACMG.xlsx

1. Select File Format:	Flexible Format V
2. Contains Column Header:	● Yes ◯ No
3. Select Identifier Type:	Please assign at least one column below as "ID", and assign the identifier type(s).
	Assign additional columns as ID to improve mapping coverage if desired.
4. Array platform used for experiments:	Not specified/applicable \checkmark Select relevant array platform as a reference set for data analysis.

5. Use the dropdown menus to specify the column names that contain identifiers and observations. For observations, select the appropriate measurement value type.

Raw Data (100) Dataset Summary (99) Metadata

ID/Observation Name	ID ~	Observatio 🗸		
		Expr Fold C V		
Measurement/Annotation				
	Gene symb V	ļ		
	Hugo_Symbol	IVA_Prediction		
	BRCA2	2		
	GJB2	2	Warning X	
	TP53	2	Your dataset does not contain any metadata.	
	ABCA3	1	Metadata is useful when you search for datasets or subsequent analyses.	
	ABCA3	2	Please click on the Metadata tab to add keywords that describe the data.	
	ABCC6			
	ACADS	2	Click OK to continue to save the dataset without metadata.	
	ACADS ACSF3	2	OK Cancel	
	AGBL5			
	AGRN	1		
	AIPL1	2		
	ALDOB	2		
	ALG13	1		
	APOC3	2		
	AQP5	2		
	ARMC4	2		
	ATP8B1	2		
20	BBS1	2		
21	BBS12	2		
22	BLOC153	1		
23	C9	2		
	CAPN1	2		
25	CD36	2		



Core analysis



Genes and Cher	nicals Diseases and Functions	Pathways and Lists Dat	asets and Analyses	Advanced Search			QIAGEN Land Explorer	QIAGEN
Create New	1		Searc	h				QIAGEN
Core Analysis								
Comparison Analysis	ermline_variants_ACMG							- 0 ×
Biomarker Filter	ermline_variants_ACMG							
Biomarker Comparison Analysis) All IDs (99) Metadata							
MicroRNA Target Filter	, , , , , , , , , , , , , , , , , , ,							
BioProfiler	List Create Dataset Cu	ustomize Table					Symbol ABCA3 - WFS1 (1/1) 🕥	\ll >>
IsoProfiler								
	ID	Flags	🗵 🔬 Symbol		Location	X Type(s)	🗵 Drug(s)	×
My Pathway	ABCA3	D	ABCA3*	ATP binding cassette subfamily A member 3		transporter		
Path Designer	ABCA3	D	ABCA3*	ATP binding cassette subfamily A member 3		transporter		
Filter Dataset	ABCC6		ABCC6	ATP binding cassette subfamily C member 6	Plasma Membrane	transporter		
Upload Dataset	ACADS	D	ACADS*	acyl-CoA dehydrogenase short chain	Cytoplasm	enzyme		
Advanced Search	ACADS	D	ACADS*	acyl-CoA dehydrogenase short chain	Cytoplasm	enzyme		
	ACSF3		ACSF3	acyl-CoA synthetase family member 3	Cytoplasm	enzyme		
Project	AGBL5		AGBL5	AGBL carboxypeptidase 5	Cytoplasm	peptidase		
Compare	AGRN		AGRN	agrin	Plasma Membrane	other		
Import Pathway	AIPL1		AIPL1	aryl hydrocarbon receptor interacting prot	Nucleus	other		
2.000	ALDOB		ALDOB	aldolase, fructose-bisphosphate B	Cytoplasm	enzyme		
1.000	ALG13		ALG13	ALG13 UDP-N-acetylglucosaminyltransfer	Cytoplasm	enzyme		
2.000	APOC3		APOC3	apolipoprotein C3	Extracellular Space	transporter	volanesorsen	
2.000	AQP5		AQP5	aquaporin 5	Plasma Membrane	transporter		
2.000	ATP8B1		ATP8B1	ATPase phospholipid transporting 8B1	Plasma Membrane	transporter		
2.000	BBS1		BBS1	Bardet-Biedl syndrome 1	Extracellular Space	other		
2.000	BBS12		BBS12	Bardet-Biedl syndrome 12	Extracellular Space	other		
1.000	BLOC153		BLOC153	biogenesis of lysosomal organelles compl	Cytoplasm	transporter		
2.000	BRCA2		BRCA2	BRCA2 DNA repair associated	Nucleus	transcription regulator		
2.000	C9		C9	complement C9	Extracellular Space	other		
2.000	CAPN1		CAPN1	calpain 1	Cytoplasm	peptidase	alicapistat, BLD-2660	
2.000	CD36		CD36	CD36 molecule	Plasma Membrane	transmembrane receptor	VT1021, zeaxanthin	
2.000	CD96		CD96	CD96 molecule	Plasma Membrane	other	GSK6097608	
1.000	CDHR1		CDHR1	cadherin related family member 1	Plasma Membrane	other		
2.000	CDKAL1		CDKAL1	CDK5 regulatory subunit associated protei	. Cytoplasm	enzyme		
1.000	CHD7		CHD7	chromodomain helicase DNA binding prot.	• •	enzyme		
2.000	CIB2		CIB2	calcium and integrin binding family memb.		kinase		
2.000	ICK		CILK1	ciliogenesis associated kinase 1	Cytoplasm	kinase		
2.000	CLCN1		CLCN1	chloride voltage-gated channel 1	Plasma Membrane	ion channel		
1.000	CLN8		CLN8	CLN8 transmembrane ER and ERGIC protein		other		
					2 P			

0 / 99 Flags:

"D" - Duplicates. Gene/Protein/Chemical identifiers marked with an asterisk indicate that multiple identifiers in the dataset file map to a single gene/chemical in the Global Molecular Network.

"O" - Override molecules. Gene/Protein/Chemical identifiers marked as "Override" are displayed with italic text.

"A" - Gene/Protein/Chemical ID marked as Absent. The gene/protein/chemical will not be used as a focus molecule or appear in networks unless you also explicitly override this flag with the Override column.

Predet Variant Effects Analysis - [analysis : Nature_comm_2020_germline_variants_ACMG] Set Cutoffing Biological Filters Set Cutoffing Oppulation of genes to consider for p-value calculations: Reference Set Networks Interaction & Ca. Reference Set Ingenuity Knowledge Base (Genes Only) Reference Set Ingenuity Knowledge Base (Genes Only) Reference Set Ingenuity Knowledge Base (Genes Only) Relationships to consider Node Types biologic drug. Data Sources All Data Sources All Direct Relationships Species All Cites & Cell Lines All Propose the propose th						
Set Cutoffs Biological Filters > General Settings Population of genes to consider for p-value calculations: Networks Interaction & Ca @ Reference Set Ingenuity Knowledge Base (Genes Only) Node Types biologic drug @ Node Types biologic drug @ Affects networks and upstream regulator analysis Optional Analyses: MiRNA Confidence Experi @ Data Sources All @ Direct Relationships Direct Relationships MiRNA Confidence Experi @ Species All @ Tissues & Cell Lines All @	Create New	Genes and Che	emicals Diseases and Functions Pathways and Lists Datasets and Analyses	Search Advanced Search	QIAGEN Land Explorer	
> General Settings Population of genes to consider for p-value calculations: Networks Interaction & Ca Reference Set Ingenuity Knowledge Base (Genes Only) Consider only molecules and/or relationships where (confidence Experimentally Observed) AND (mol. types = biologic drug OR connoical pathway OR chemical - endogenous mammalian OR chemical - endogenous mammalian OR chemical - kinase inhibitor OR chemical - endogenous mammalian OR chemical - kinase inhibitor OR chemical - endogenous mammalian OR chemical - endogenous non-mammalian OR chemical - kinase inhibitor OR chemical - endogenous non-mammalian OR chemical - kinase inhibitor OR chemical - endogenous non-mammalian OR chemical - kinase inhibitor OR chemical - kinase OR numer on Population Signat - Optional Analyses: Data Sources All ImiRNA Confidence Experime ImiRNA Confidence Experime ImiRNA Confidence Experime ImiRNA Confidence Experimentary on Congrup OR growth factor OR ion channel OR kinase OR populates OR related pathway node OR transcription regulator OR transporter) ImiRNA Confidence Experimentary on Congrup OR transporter) ImiRNA Confidence Exper	Create Variant Effects	ts Analysis - [analysis	s : Nature_comm_2020_germline_variants_ACMG]		- 0 :	×
> General Settings Population of genes to consider for p-value calculations: Networks Interaction & Ca Cansider only molecules and/or relationships where Networks Interaction & Ca Reference Set Ingenuity Knowledge Base (Genes Only) Node Types biologic drug Consider: Node Types biologic drug Consider: Affects networks and upstream regulator analysis Data Sources All My Project Obirect Relationships My Project Obirect Relationships My Remicral - endogenous non-manualian OR chemical - kinase inhibitor OR chemical - analyses: MiRNA Confidence Experi Direct Relationships Species All Direct Relationships Tissues & Cell Lines All Consider only molecules and/or related pathway onde OR transcription regulator OR Tissues & Cell Lines All Population of genes to consider:	Set Cutoffs Biol	logical Filters			0	
Mutation All Save As Default	Networks Intera Node Types bic Data Sources A miRNA Confider Species All Tissues & Cell Li Mutation All	action & Ca 2 ologic drug 2 All 2 ence Experi 2 Lines All 2	Reference Set Ingenuity Knowledge Base (Genes Only) Relationships to consider: Affects networks and upstream regulator analysis Image: Direct and Indirect Relationships	✓ ✓ My Project ✓ My Pathways	Consider only molecules and/or relationships where (confidence = Experimentally Observed) AND (mol. types = biologic drug OR canonical pathway OR chemical - endogenous mammalian OR chemical - endogenous non-mammalian OR chemical - kinase inhibitor OR chemical - other OR chemical - protease inhibitor OR chemical drug OR chemical reagent OR chemical toxicant OR complex OR cytokine OR disease OR enzyme OR function OR G-protein coupled receptor OR group OR growth factor OR ion channel OR kinase OR ligand-dependent nuclear receptor OR mature microRNA OR microRNA OR other OR peptidase OR phosphatase OR related pathway node OR transcription regulator OR	

Advanced

Recalculate 92 analysis-ready molecules (0 Down and 92 Up)

Preview Dataset Nature_comm_2020_germline_variants_ACMG

Analysis-Ready (92) Mapped IDs (99) Unmapped IDs (0) All IDs (99) Metadata

Add To My Pathway	Add To My List Create Dataset	Customize Table						
Variant ACMG Classification	× ID	Flags	🗵 🔬 Symbol	T 🗵 Entrez Gene Name	× Location	X Type(s)	X Drug(s)	×
2.000	ABCA3	D	ABCA3*	ATP binding cassette subfamily A membe.	e Plasma Membrane	transporter		
1.000	ABCC6		ABCC6	ATP binding cassette subfamily C membe.	e Plasma Membrane	transporter		
2.000	ACADS	D	ACADS*	acyl-CoA dehydrogenase short chain	Cytoplasm	enzyme		
1.000	ACSF3		ACSF3	acyl-CoA synthetase family member 3	Cytoplasm	enzyme		
2.000	AGBL5		AGBL5	AGBL carboxypeptidase 5	Cytoplasm	peptidase		
1.000	AGRN		AGRN	agrin	Plasma Membrane	other		
2.000	AIPL1		AIPL1	aryl hydrocarbon receptor interacting pro.) Nucleus	other		

0/92

Flags:

"Bold" - Focus molecules. Gene/Protein/Chemical identifiers that meet the user-defined cutoff and map to the Global Molecular Network are displayed with bold text.

"D" - Duplicates. Gene/Protein/Chemical identifiers marked with an asterisk indicate that multiple identifiers in the dataset file map to a single gene/chemical in the Global Molecular Network.

"O" - Override molecules. Gene/Protein/Chemical identifiers marked as "Override" are displayed with italic text.

"A" - Gene/Protein/Chemical ID marked as Absent. The gene/protein/chemical will not be used as a focus molecule or appear in networks unless you also explicitly override this flag with the Override column.

Cancel

Run Analysis

RUN






Summary Graphical Summary Pathways Upstream Analysis Diseases & Functions Regulator Effects Netwo	rks Lists Analysis Match Molecules	
Export: 🐼 🕻		
> Experiment Metadata		
> Analysis Settings		
Top Canonical Pathways		
Name	p-value	Overlap
Retinoid metabolism and transport		9.1 % 4
Plasma lipoprotein assembly, remodeling, and clearance	3.18E-04	5.3 % 4
HDR through MMEJ (alt-NHEJ)	1.16E-03	16.7 % 2
Sirtuin Signaling Pathway	1.41E-03	2.1 % 6/2
Sensory processing of sound by outer hair cells of the cochlea	1.69E-03	5.5 % 3
 Upstream Regulators Name 	p-value	Predicted Activati
SREBF1	2.26E-05	
ASGR1	• 5.22E-05	
ASGR1 PPARGC1A SIRT1	5.22E-05 1.82E-04 2.82E-04	
ASGR1 PPARGC1A	• 5.22E-05 • 1.82E-04	
ASGR1 PPARGC1A SIRT1	5.22E-05 1.82E-04 2.82E-04 2.96E-04	
ASGR1 PPARGC1A SIRT1 OSM V Causal Network Name	5.22E-05 1.82E-04 2.82E-04 2.96E-04	Predicted Activati
ASGR1 PPARGC1A SIRT1 OSM V Causal Network Name PRKCE	5.22E-05 1.82E-04 2.82E-04 2.96E-04	Predicted Activati
ASGR1 PPARGC1A SIRT1 OSM V Causal Network Name PRKCE GAB2	5.22E-05 1.82E-04 2.82E-04 2.96E-04 1.23456789 p-value p-value 2.54E-06 6.99E-06	Predicted Activati
ASGR1 PPARGC1A SIRT1 OSM V Causal Network Name PRKCE GAB2 BCR (complex)	5.22E-05 1.82E-04 2.82E-04 2.96E-04 p-value 2.54E-06 6.99E-06 7.63E-06	Predicted Activati
ASGR1 PPARGC1A SIRT1 OSM Causal Network Name PRKCE GAB2 BCR (complex) AGER	5.22E-05 1.82E-04 2.82E-04 2.96E-04 123456789 > p-value 2.54E-06 6.99E-06 7.63E-06 8.99E-06	Predicted Activati
ASGR1 PPARGC1A SIRT1 OSM Causal Network Name PRKCE GAB2 BCR (complex)	5.22E-05 1.82E-04 2.82E-04 2.96E-04 p-value 2.54E-06 6.99E-06 7.63E-06	Predicted Activati






Analysis: Nature_comm_2020_germline_variants_ACMG - 2024-03-20 05:07 下午



© 2000-2024 QIAGEN. All rights reserved.



HDR through MMEJ (alt-NHEJ) : Nature_comm_2020_germline_variants_ACMG : Variant ACMG Classification








Variant Effects Analysis - Nature_						- 0
Summary Graphical Summar	ry Pathways	Upstream Analysis	Diseases & Functions Regulator Effects N	Networks Lists Analysis Match Molecules		
Upstream Regulators Causal	Networks					
Add To My Pathway Add	d To My List	Display as Network	Activity Plot Customize Table Me	chanistic Networks 🛛 📇 🗰 🔅	p-va 7.73E-08 - 6.70E-04 (1/22) 🗸 🕅	» 🕟
Jpstream Regulator	▼ × Variant	ACMG Classification	▼ × Molecule Type	T X p-value of overlap T X	Target Molecules in Dataset T × Mechanistic Network	т
SREBF1			transcription regulator	Molecule Type	ACADS, +APOC3, +CD36, +G6PC1,all 10 36 (12)	
MED13			transcription regulator	 Unfiltered 	CD36, +CIB2, +G6PC1, +ODAD2, +all 5	
CTNNB1			transcription regulator	Genes, RNAs, and Proteins	ABCA3, ACADS, AGRN, AQP5,all 16	
PPARGC1A			transcription regulator	O Drugs and Chemicals	ACADS, +APOC3, +CD36, +G6PC1,all 11 26 (11)	
pirinixic acid			chemical toxicant	Select from list below	ACADS, +C9, +CD36, +G6PC1, +Lall 10 37 (13)	
enofibrate			chemical drug	<u> </u>	APOC3, +CD36, +G6PC1, +LDLR, +all 8 37 (14)	
serine			chemical - endogenous mammalian	chemical - endogenous mammalian	PCK2, +PHGDH, +TP53all 3	
VR4A1			ligand-dependent nuclear receptor	chemical - endogenous non-mammalian	ALDOB, +CD36, +G6PC1, +GNRHR,*all 8 27 (11)	
NR1D1			ligand-dependent nuclear receptor	chemical - kinase inhibitor	APOC3, +G6PC1, +KLB, +TSHBall 4	
EP			growth factor	chemical - other	ALDOB, +CD36, +G6PC1, +GNRHR,all 10 32 (14)	
-bromo-cAMP			chemical reagent	chemical - protease inhibitor	BRCA2, +G6PC1, +GNRHR, +ITGA8,all 10 31 (11)	
rtepillin C			chemical reagent		G6PC1, +LDLR, +PCSK9all 3 27 (7)	
BXW7			enzyme	✓ chemical drug	CD36, +IVD, +LDLR, +LIPA, +TP53all 5 28 (7)	
MTDH			transcription regulator	chemical reagent	ALDOB, +C9, +CD36, +LDLR, +PCSall 6 27 (7)	
NU 1025			chemical toxicant	Analy	BRCA2, ↑TP53all 2	
PRKAA			group	Apply Cancel	CD36, +G6PC1, +OGG1, +TP53all 4 35 (13)	
amoxifen			chemical drug	5.05E-05	↑ABCA3, ↑BRCA2, ↑CD36, ↑GJB2, ↑all 8 30 (8)	
ИАР4К4			kinase	6.62E-05	↑ACADS, ↑IVD, ↑NDUFS1, ↑PHYH, ↑all 5	
PARA			ligand-dependent nuclear receptor	6.88E-05	↑ACADS, ↑ALDOB, ↑APOC3, ↑C9, ↑all 9 23 (11)	
1QL3			other	7.40E-05	↑CD36, ↑G6PC1all 2 17 (6)	
holesterol ester			chemical - endogenous mammalian	7.40E-05	↑CD36, ↑LDLRall 2	
				7.50E-05	↑ALDOB, ↑APOC3, ↑CD36, ↑G6PC1,all 11 37 (14)	
nsulin			group			
PPARG			ligand-dependent nuclear receptor	1.09E-04	↑ABCA3, ↑ACADS, ↑CD36, ↑G6PC1, 1all 9 38 (13)	
THRB			ligand-dependent nuclear receptor	1.18E-04	↑APOC3, ↑G6PC1, ↑LDLR, ↑PHYH, ↑all 7 31 (8)	
DGA			enzyme	1.37E-04	↑CAPN1, ↑CD36, ↑CDKAL1, ↑CILK1, 1all 8	
GF21			growth factor	1.89E-04	↑G6PC1, ↑KLB, ↑LDLR, ↑PHGDHall 4 28 (7)	
terol			chemical - endogenous mammalian	1.98E-04	↑LDLR, ↑LIPA, ↑PCSK9all 3 4 (3)	
IF2AK3			kinase	2.16E-04	↑CAPN1, ↑COG8, ↑PCK2, ↑TP53, ↑all 5	
itamin A			chemical - endogenous mammalian	2.17E-04	↑LRAT, ↑STRA6, ↑TSHBall 3	
laparib			chemical drug	2.39E-04	↑BRCA2, ↑IFIH1, ↑RBBP8, ↑TP53all 4	
launorubicin			chemical drug	2.82E-04	↑ABCA3, ↑ABCC6, ↑TP53all 3	
yclopropanecarboxylic acid			chemical reagent	3.06E-04	ACADS, AGPC1, ATP53all 3	
lexamethasone			chemical drug	3.16E-04	↑ABCC6, ↑ACADS, ↑ALDOB, ↑AQP5,all 20 30 (10)	
USF1			transcription regulator	3.37E-04	*BRCA2, *G6PC1, *LDLR, *TP53all 4	
elaidic acid			chemical - endogenous mammalian	3.37E-04	LDLR, LIPA, PCSK9, PHGDHall 4	

Selected 0 / 1090



Chemical drug upstream





\sim	\sim

A 1.1		ALC: 1
Add	to	Network

Selecting regulators in the network filters the table.

The entries in the table show how a target (row) supports the prediction of a regulator (column) in the network above.

🛆 Target	Variant ACMG Classifica	Molecule Type	tamoxifen	▼ × TGFB1	τ× LEP	▼ × USF1	T × PPARG	Y × PPARGC1A	▼ × SREBF1	T × FOXO1	τ×
ABCA3	† 2.000	transporter	Affected				Affected				
ACADS	† 2.000	enzyme					Affected	Affected	Affected		
ALDOB	† 2.000	enzyme		Affected	Affected					Affected	
APOC3	† 2.000	transporter						Affected	Affected	Affected	
BRCA2	† 2.000	transcription regulator	Affected	Affected		Affected					
CD36	† 2.000	transmembrane receptor	Affected	Affected	Affected		Affected	Affected	Affected	Affected	
CDHR1	1 .000	other		Affected							
G6PC1	1 2.000	phosphatase		Affected	Affected	Affected	Affected	Affected	Affected	Affected	
GJB2	1 2.000	transporter	Affected	Affected							
CNIDHD	*1 000	C protain coupled receptor	Affected		Affected						
Selected/Total targets: 0/30											

Sample to Insight

0


00000	
	Disease & function



– 🗗 🛛

Variant Effects Analysis - Nature_comm_2020_germline_variants_ACMG - 2024-03-20 05:07 下午


Summary Graphical Summary Pathways Upstream Analysis Diseases & Functions Regulator Effects Networks Lists Analysis Match Molecules



Add To My Pathway 🛛 Add To My List 🔹 Annotation 🔹 Activity Plot 🔄 Display as Network 🔹 Customize Table 🗧 🏢

p-value 4.84E-21 - 7.93E-07 (1/10) 🗸 🔍 🚿

Categories T	Diseases or Functions Annotation	r 🛆 p-value	▼ × Predicted Activation State	T × Activation z-score T 2	× Molecules	▼ × # Molecules	τ×
Hereditary Disorder,Neurological Disease,Organis	Familial neurological disorder	4.84E-21			↑AGRN, ↑ALG13, ↑BBS1, ↑BBS12, ↑BRC	all 53 53	
Hereditary Disorder, Neurological Disease, Organis	Autosomal recessive neurological disorder	9.95E-21			↑AGRN, ↑BBS1, ↑BBS12, ↑BRCA2, ↑CA	all 35 35	
Hereditary Disorder,Ophthalmic Disease,Organis	Hereditary Eye Disease	2.19E-20			↑AGBL5, ↑AIPL1, ↑BBS1, ↑BBS12, ↑BLO	all 28 28	
Ophthalmic Disease,Organismal Injury and Abno	Retinitis pigmentosa	3.76E-17			AGBL5, AIPL1, BBS1, BBS12, CD	all 16 16	
Hereditary Disorder,Ophthalmic Disease,Organis	Hereditary retinitis pigmentosa	5.38E-17			↑AGBL5, ↑AIPL1, ↑BBS1, ↑CDHR1, ↑CIB2,	all 15 15	
Hereditary Disorder,Ophthalmic Disease,Organis	Hereditary retinal degeneration	1.07E-16			↑AGBL5, ↑AIPL1, ↑BBS1, ↑BBS12, ↑C9, ト	all 18 18	
Hereditary Disorder,Ophthalmic Disease,Organis	Autosomal recessive retinitis pigmentosa	2.74E-15			↑AGBL5, ↑AIPL1, ↑CDHR1, ↑CIB2, ↑CLR	all 12 12	
Developmental Disorder,Ophthalmic Disease,Org	Developmental disorder of retina	2.61E-14			AGBL5, AIPL1, BBS1, BBS12, CD	all 15 15	
Cellular Function and Maintenance,Organ Develo	Maintenance of photoreceptors	8.90E-14			↑BBS1, ↑BBS12, ↑CDHR1, ↑CIB2, ↑CLN8,	all 9 9	
Ophthalmic Disease,Organismal Injury and Abno	Retinal degeneration	9.31E-14		0.000	↑AGBL5, ↑AIPL1, ↑BBS1, ↑BBS12, ↑C9, ト	all 19 19	
Hereditary Disorder, Ophthalmic Disease, Organis	Autosomal recessive retinal degeneration	1.04E-13			↑AGBL5, ↑AIPL1, ↑CDHR1, ↑CIB2, ↑CLR	all 13 13	
Developmental Disorder,Hereditary Disorder,Oph	Retinal dystrophy	1.35E-13			↑AGBL5, ↑AIPL1, ↑BBS1, ↑BBS12, ↑CD	all 14 14	
Ophthalmic Disease,Organismal Injury and Abno	Disease of retina	2.01E-13		0.000	↑ABCC6, ↑AGBL5, ↑AIPL1, ↑BBS1, ↑BBS	all 25 25	
Hereditary Disorder, Neurological Disease, Organis	Familial central nervous system disease	4.45E-13			ALG13, *BBS1, *BBS12, *BRCA2, *C9,	all 39 39	
Selected 0 / 1000							







Summary Graphical Su	ature_comm_2020_germline_variants_ ummary Pathways Upstream A		Regulator Effects Networ	ks Lists Analysis Match	Molecules			- 0
Add To My Pathway	Add To My List Create Datas	set Customize Table) 🖦 🗘					
Symbol	▼ Entrez Gene Name ▼ ×	Identifier + Gene Symbol - human T ×	Variant ACMG Classific T ×	Location T ×	Type(s) T >	Biomarker Application(s) T ×	Drug(s)	т
BCA3*	ATP binding cassette subfamily	ABCA3*	Pathogenic	Plasma Membrane	transporter			
ABCC6	ATP binding cassette subfamily	ABCC6	Likely Pathogenic	Plasma Membrane	transporter			
ACADS*	acyl-CoA dehydrogenase short	ACADS*	Pathogenic	Cytoplasm	enzyme	unspecified application		
VCSF3	acyl-CoA synthetase family me	ACSF3	Likely Pathogenic	Cytoplasm	enzyme			
AGBL5	AGBL carboxypeptidase 5	AGBL5	Pathogenic	Cytoplasm	peptidase			
AGRN	agrin	AGRN	Likely Pathogenic	Plasma Membrane	other			
AIPL1	aryl hydrocarbon receptor inter	AIPL1	Pathogenic	Nucleus	other			
LDOB	aldolase, fructose-bisphosphate	ALDOB	Pathogenic	Cytoplasm	enzyme			
LG13	ALG13 UDP-N-acetylglucosami	ALG13	Likely Pathogenic	Cytoplasm	enzyme			
POC3	apolipoprotein C3	APOC3	Pathogenic	Extracellular Space	transporter	diagnosis, efficacy	volanesorsen	
QP5	aquaporin 5	AQP5	Pathogenic	Plasma Membrane	transporter			
TP8B1	ATPase phospholipid transporti	ATP8B1	Pathogenic	Plasma Membrane	transporter			
BS1	Bardet-Biedl syndrome 1	BBS1	Pathogenic	Extracellular Space	other			
BS12	Bardet-Biedl syndrome 12	BBS12	Pathogenic	Extracellular Space	other			
LOC153	biogenesis of lysosomal organe	BLOC1S3	Likely Pathogenic	Cytoplasm	transporter	diagnosis		
RCA2	BRCA2 DNA repair associated	BRCA2	Pathogenic	Nucleus	transcription regulator	diagnosis, efficacy,		
9	complement C9	C9	Pathogenic	Extracellular Space	other	unspecified application		
APN1	calpain 1	CAPN1	Pathogenic	Cytoplasm	peptidase	conference of frances	BLD-2660, alicapistat	
D36	CD36 molecule	CD36	Pathogenic	Plasma Membrane	transmembrane receptor	efficacy, unspecified application		
D96	CD96 molecule	CD96	Pathogenic	Plasma Membrane	other	encedy, anopeened appreciation	GSK6097608	
DHR1	cadherin related family member 1	CDHR1	Likely Pathogenic	Plasma Membrane	other		0010001000	
DKAL1	CDK5 regulatory subunit associ	CDKAL1	Pathogenic	Cytoplasm	enzyme			
HD7	chromodomain helicase DNA bi	CHD7	Likely Pathogenic	Nucleus	enzyme			
3B2	calcium and integrin binding fa	CIB2	Pathogenic	Cytoplasm	kinase			
ILK1	ciliogenesis associated kinase 1	ICK	Pathogenic	Cytoplasm	kinase			
LCN1	chloride voltage-gated channel 1	CLCN1	Pathogenic	Plasma Membrane	ion channel			
LN8	CLN8 transmembrane ER and E	CLN8	Likely Pathogenic	Cytoplasm	other			
LPB	ClpB family mitochondrial disag		Likely Pathogenic	Nucleus	transcription regulator			
LRN1	clarin 1	CLRN1	Pathogenic	Plasma Membrane	other			
NGB1	cyclic nucleotide gated channel	CNGB1	Likely Pathogenic	Plasma Membrane	ion channel			
OG8	component of oligomeric golgi	COG8	Pathogenic	Cytoplasm	transporter			
NAAF4	dynein axonemal assembly fact	DYX1C1	Likely Pathogenic	Nucleus	other			
OCK7	dedicator of cytokinesis 7	DOCK7	Likely Pathogenic	Plasma Membrane	other			
LMOD3	ELMO domain containing 3	ELMOD3	Pathogenic	Other	other			
LINODS	cento domain containing 5	LEWODS	radiogenic	ound	ound			

en a

Selected/Total molecules: 0 / 92







Draw customer pathway



Diseases and Functions Genes and Chemicals Pathways and Lists Datasets and Analyses

Create New...

学司险甘中助人



– 🗗 🗙

Annotated Dataset: myList

Preview Dataset myList

Mapped IDs (16) Unmapped IDs (0) All IDs (16) Metadata

Add To My Pathway	New My Pathway	ate Dataset Customize Table					
ID	Saved My Pathway	🗵 🖉 Symbol	TX	Entrez Gene Name	Location	X Type(s)	× Drug(s)
ERGIC1	New My Pathway 6	ERGIC1		endoplasmic reticulum-golgi intermediate c	Cytoplasm	other	
GNA12		GNA12		G protein subunit alpha 12	Plasma Membrane	enzyme	
HLA-DRB1		HLA-DRB1		major histocompatibility complex, class II, D	Plasma Membrane	transmembrane receptor	apolizumab
LINC01271		LINC01271			Other	other	
LOC105373831		LOC105373831		uncharacterized LOC105373831	Other	other	
PDGFB		PDGFB		platelet derived growth factor subunit B	Extracellular Space	growth factor	dasatinib, sunitinib, pegpleranib, imatinib/
PITX1-AS1		PITX1-AS1		PITX1 antisense RNA 1	Other	other	
PLCL1		PLCL1		phospholipase C like 1 (inactive)	Cytoplasm	enzyme	quinacrine
PNKD		PNKD		PNKD metallo-beta-lactamase domain conta	Nucleus	other	
PRDM1		PRDM1		PR/SET domain 1	Nucleus	transcription regulator	
RPS21P8		RPS21P8		ribosomal protein S21 pseudogene 8	Other	other	
SFMBT1		SFMBT1		Scm like with four mbt domains 1	Nucleus	transcription regulator	
SMAD3		SMAD3		SMAD family member 3	Nucleus	transcription regulator	
SMAD7		SMAD7		SMAD family member 7	Nucleus	transcription regulator	
TET2		TET2		tet methylcytosine dioxygenase 2	Nucleus	enzyme	
ZBTB40		ZBTB40		zinc finger and BTB domain containing 40	Nucleus	transcription regulator	

Search

Advanced Search

16/16


Flags:

"D" - Duplicates. Gene/Protein/Chemical identifiers marked with an asterisk indicate that multiple identifiers in the dataset file map to a single gene/chemical in the Global Molecular Network.

"O" - Override molecules. Gene/Protein/Chemical identifiers marked as "Override" are displayed with italic text.

"A" - Gene/Protein/Chemical ID marked as Absent. The gene/protein/chemical will not be used as a focus molecule or appear in networks unless you also explicitly override this flag with the Override column.

Edit Dataset Settings Analyze/Filter Dataset ¥ Close



🛛 New My Pathway 6

📩 🍓 🗟 Edit: 😰 💭 🗟 📾 📾 🇭 🖓 🍕 Build	Overlay Path Designer	Pattern Search Vie	w: 🔀 💥 🍝 👌	Zoom:	🔄 🔍 Export: 🐼 🎫 🔤 »
Tool: Connect ~	< New My Pathway 6 > ≈ ▲	PP (4)			RB(1)
11 relationships (or 192 Findings) were added.	• 23 •		Λ	Λ	
Filter Summary	+	$\sqrt{\mathcal{V}}$	GNA)2	PLC1	
Consider all molecules and/or relationships	+ "	ILA-DRB1	V	V	\mathbf{N}
		\mathbf{O}			
✓ General Settings	•			1	
Interactions				071	
✓ Direct ✓ Indirect	L	LOC105373831	LINCO		
> Data Sources All		\smile			
				E (1)	
> miRNA Confidence Level All					
			CEMPTA		
> Species All	K K	H52 P0	SFMBT)	ZBTB40	-
> Tissues & Cell Lines All					
> Mutation All		E.PP. RE. T (9)	1		
> Relationship Types All			A . M. PD. PP.	TR, UB (15) A E, I, L, P, PP, I	RB, T, TR, UB (27)
	e e	RDM1	SMAD7, PD, PP, RB.	SMAD3	
> Publication Date Range All			PD, PP, RB,	T, TR	
> Node Types All					
> Node Types All			т	1)	
> Diseases All		\sim	PR (4)		
	E				
> Biofluids All	-	-	FUGED	RINKD	
Save As Preferences Restore From Prefs Reset Apply	© 2000-2023 QIAGEN. All rights	s reserved.			
Save As Preferences Restore From Prefs Reset Apply	^				



Genes and Chemicals Diseases and Functions Pathways and Lists Datasets and Analyses	
Create New activation of T lymphocytes Search	QIAGEN Land Explorer
Project Manager Search Results	– 🗆 ×
Genes and Chemicals Diseases and Functions	
My Projects ✓ My Projects Add To My Pathway New My Pathway notations Effect on Function BioProfiler Activity Plot Show Functions Expand Functions	<u>д</u>
Dataset Files The search for activation o Saved My Pathway B diseases and functions.	
To Diseases & Functions	
 Ulcerative Colitis-associations2 Matching Diseases & F. 	1421
🗎 Ulcerative Colitis-associations 🛛 F 🗸 🔲 Hematological System Development and Function	1372
Analyses activation Ac	1137
🖆 colon cancer-association - 2023 💦 > 📄 Activation of lymphocytes	1134
 Ulcerative Colitis-associations - Comparison Analyses Activation of T lymphocytes 	877
Biomarker Filter Results Activation of natural killer cells [activation of NK Lymphocyte, activation of NK cells,]	262
Biomarker Comparison Analyses A Activation of B lymphocytes [activation of B-enriched lymphocytes, activation of primary B lymphocytes]	254
MicroRNA Target Filter Results	163
IsoProfiler Results	130
My Pathways My Lists Activation of helper T lymphocytes [activation of helper inducer T lymphocytes]	88
> Human Genes Chromosomal Locatic 🕺 > 🗌 Activation of cytotoxic T cells [activation of cytotoxic T lymphocytes, activation	87
Activation of natural killer T lymphosytes	59
Activation of regulatory Thymphocytes	58
Activation of memory T lymphocytes	49
Activation of Th1 cells [activation of Th1 lymphocytes activation of T helper typ OK Cancel	40
Activation of naive lymphocytes	35
Activation of effector lymphocytes	34
Activation of naive T lymphocytes	32
> Activation of alpha-beta T lymphocytes [activation of α -β T lymphocytes]	29
Activation of mature T lymphocytes	28
Activation of effector T lymphocytes	27
Activation of peripheral blood lymphocytes	26
Activation of Th2 cells [activation of Th2 lymphocytes, activation of th2 effector cells,]	24




New My Pathway 6


New My Pathway 6		
📩 🏰 🗟 Edit: 😰 💭 🚳 📾 👘 ᡝ 🕞 🤤 Build		📄 »
Tool: Connect	New My Pathway 6	< e
11 relationships (or 192 Findings) were added.		
Filter Summary Consider all molecules and/or relationships	HLA-DRB1 GNA12 PLCU1 TET2	
V General Settings		
Interactions Indirect	LINC01271 PITX1-AS1	
> Data Sources All	LOC105373831	
> miRNA Confidence Level All	Activation of T lymphocytes	
> Species All	RP(S2)P8 (SFMBT) (ZBTB40)	* 0 0
> Tissues & Cell Lines All		
> Mutation All		
> Relationship Types All		
> Publication Date Range All	PRDM1 (SMAD7) (SMAD3)	
> Node Types All		
> Diseases All		
> Biofluids All	ERGIC1 PDGFB RNKD	
Save As Preferences Restore From Prefs Reset Apply	© 2000-2023 OIAGEN, All rights reserved.	ese (Traditiona

– 🗆 x 🎽


🛛 New My Pathway 6




🗙 New My Pathway 6



🛛 New My Pathway 6



X New My Pathway 6



ΟX

忨

_

New My Pathway 6

My Pathways				- • ×
New My Pathway 6				位
🤇 🎒 🎼 Edit: 😰 🕄 🗟 🖉 💼 🗭 🕞 🤤 Build	Overlay Path Designer	Pattern Search View: 💱 💥 ≶	Ž≣ TT I Zoom: ∅	🕰 Export: 🐼 🎫 📴 »
Tool: Keep	< New My Pathway 6		RB (D)	<
8 nodes and 15 relationships were kept			Λ $i \Lambda i$	
Filter Summary	• • • • • • • • • • • • • • • • • • • •	GNA)2		
Keep all molecules where connectedness > 1	+			
> Data Sources			01)271 PITK1-AS1	
> miRNA Confidence Level	I I I I	LOC1053 3831 Activation of T lypp		
> Species	-	S SMA		
> Tissues & Cell Lines		RRS21P8	ZBTB 40	
> Mutation		IL Phraul	C Q LO, PP, RB (149) Dobulin	
> Relationship Types		(PRDM1)	PP, TR, UB-20) A. C. I, L. P. PP, RB, T, TR, UB (27)	:
> Publication Date Range		SMAD7.PD.PP.	RE.T.TR.SMAD3	
> Node Types		(The	тю	
> Diseases	© 2000-2023 QIAGEN. All righ	ERGID1 PDGFB	FNKD	
> Biofluids		Highlight	View Shortest Paths + 1 (389)	✓ Paths 1 - 50 ✓ 《 《
> Biomarkers	Paths	Set A Molecules	Node 1	Set B Molecules
> Node Fill Overlay	✓ 1 SMAD3	SMAD4	Activat	ion of T lymphocytes
V Node Connectivity	2 SMAD3	IL2	Activat	ion of T lymphocytes
	3 PRDM1	IL2	Activat	ion of T lymphocytes
Nodes connected to > V 1 other nodes	✓ 4 HLA-DRB			ion of T lymphocytes
s	5 HLA-DRB			ion of T lymphocytes
Reset Apply	6 PRDM1	Immunoglob	ulin Activat	ion of T lymphocytes

– 🗆 X

🛛 New My Pathway 6

<u> </u>					
📩 📸 🗟 Edit: 📝 💭 📾 📾 💼 🗲) (7 🔍 Build			ew: 👯 💥 🤧 👹 🔟	📃 Zoom: 🔄 🙉 Export: 🐼 🎟 🎰
Tool: Keep	~		6		
nodes and 15 relationships were kept	0		() ⁴⁴		
Filter Summary		•			
Keep all molecules where connectedness > 1		+			
> Data Sources	U		N N	CB	
> miRNA Confidence Level	0	T T		E.O.	
> Species	0		A	ctivation of T lypped es	
> Tissues & Cell Lines	0			(m) 2 (m) 2	
> Mutation	0			C C LO, PP, RS (4	49)
> Relationship Types	0	:	PRDM1	LO 2 A.E. L. M. PD. PP. TR. US 5) A.E. I.	L, P, PP, R8, T, TR, UB (27)
> Publication Date Range	0		\bigcirc	SMAD7, PD, PP, RB, T, TR, SMAD3	
> Node Types	0				
> Diseases	0				
> Biofluids	0	<u>^ v</u>	EN. All rights reserved.	***	
> Biomarkers	0	Add To My Path	hway Highlight	View Short	test Paths + 1 (389) V Paths 1 - 50 V 🔍 🤇
		Paths	Set A Molecules	Node 1	Set B Molecules
> Node Fill Overlay	0	✓ 1	SMAD3	SMAD4	Activation of T lymphocytes
V Node Connectivity	0	2	SMAD3	IL2	Activation of T lymphocytes
Nodes connected to > > 1 other nodes		 3 ✓ 4 	PRDM1 HLA-DRB1	IL2 IL2	Activation of T lymphocytes Activation of T lymphocytes
]	5	HLA-DRB1	TCR	Activation of T lymphocytes
	Reset Apply]	PRDM1	Immunoglobulin	Activation of T lymphocytes

_

– 🗆 🗙

位

🛛 New My Pathway 6

💼 🍓 📑 Edit: 🔯 🕄 🗟 🖄	📑 🅥 🕞 🤤 Build	Overlay Path D	Designer Pattern Search View	· 🔀 💥 🗲 🎽 🖬 🗉	Zoom: 🕘 🖳 Export: 🐼 🏬 🚔
		< New My Pathway	6		
ool: Grow		>⊗♠	PP (A		
Molecules & Canonical Pathways Diseases &	& Functions	4 [] b			
Grow from selected molecules to selected disease	es & functions		HUL-DEB1		
siow norm selected molecules to selected diseas					
ndicate diseases or functions related to Any	\checkmark of the selected molecules				
Consider all functions		•	N	CB	
Recalculate		1	Acti	Vation of T lymp tes	
Diseases and Functions 🝸 🕖 p-value	× Molecules ×			C (86) C (86)	
Induction of actin stress fibe 3.86E-10	SMAD7, SMAD3, SMall 3			C (2)	
Proliferation of activated T ly 1.50E-09	IL2, HLA-DRB1, SMAD3all 5		1	IL Bring (Oglabulin	
Expansion of cancer stem cel 1.70E-09	SMAD7, SMAD3, SMall 3		E.P.P.RE.T Ø	TOPO	
Contractility of fibroblasts 1.70E-09	SMAD7, SMAD3, SMall 3	:	PRDM1	LO 2 A.E. L. M. PD. PP. TR. UB A.E. I. L. P. P	P.RB.T.TR. UB (27)
Differentiation of regulatory 1.86E-09	IL2, SMAD7, HLA-DRB1all 4			SMAD7, PD. PP. RB. T. TR. SMAD3	
Cytostasis of epithelial cells 2.33E-09	SMAD7, SMAD3, SMall 3				
Activation of CD4+ T-lympho 2.67E-09	IL2, HLA-DRB1, PRDM1all 4				
Formation of abscess 3.55E-09	IL2, SMAD3, SMAD4all 3				
Proliferation of lymphocytes 4.66E-09	IL2, SMAD7, HLA-DRB1all 6				
Formation of skin 4.87E-09	SMAD7, HLA-DRB1, Sall 5	© 2000-2023 QIAG	EN. All rights reserved.		
Quantity of mononuclear leu 5.62E-09	IL2, SMAD7, HLA-DRB1all 6				
Differentiation of T lymphoc 1.30E-08	IL2, SMAD7, HLA-DRB1all 5	Add To My Path	hway Highlight	View Shortest P	Paths + 1 (389) V Paths 1 - 50 V
Activation of T lymphocytes 1.71E-08	IL2, HLA-DRB1, SMAD3all 5	Paths	Set A Molecules	Node 1	Set B Molecules
Transcription of DNA 3.61E-08	IL2, SMAD7, HLA-DRB1all 6	✓ 1	SMAD3	SMAD4	Activation of T lymphocytes
Differentiation of memory T I 4.11E-08	IL2, HLA-DRB1, PRDM1all 3	2	SMAD3	IL2	Activation of T lymphocytes
Cell viability of lymphocytes 5.19E-08	IL2, SMAD3, PRDM1,all 4		PRDM1		A set of the
Transactivation 5.58E-08	IL2, SMAD7, SMAD3,all 5	3		IL2	Activation of T lymphocytes
Proliferation of tumor cells 1.14E-07	IL2, SMAD7, SMAD3,all 5	✓ 4	HLA-DRB1	IL2	Activation of T lymphocytes
Quantity of T lymphocytes 1.24E-07	IL2, SMAD7, HLA-DRB1all 5	5	HLA-DRB1	TCR	Activation of T lymphocytes
/355	Reset Apply	✓ 6	PRDM1	Immunoglobulin	Activation of T lymphocytes

– 🗆 🗙

位

🗙 New My Pathway 6

My Pathways		- L X
🗙 New My Pathway 6		
💼 🏫 🗟 Edit: 🎲 📿 🗃 📾 👘 ᡝ 🕞 🕞 Build	Overlay Path Designer Pattern Search View: 🔀 🗦	💥 ∻ 🦉 🗊 🗉 Zoom: 🕘 🕰 Export: 🐼 🎟 📾 »
	< New My Pathway 6	
Tool: Grow V		
Molecules & Canonical Pathways Diseases & Functions		
Grow from selected molecules to selected diseases & functions	HLA-DRB1	
	+	
Indicate diseases or functions related to Any v of the selected molecules		
Consider all functions	N CO	
	_\ \	_
Beseleviete	Activation of T	SMAD4
Recalculate	-	
±		c (99) (c (99)
Diseases and Functions T / p-value X Molecules T X Induction of actin stress (Diseases and Functions AD3, SMall 3	10 m	
Proliferation of activated Functions to include: (use * for wildcard)B1, SMAD3all 5		
Expansion of cancer stem proliferation* AD3, SMall 3	PROPERT ON	
Contractility of fibroblast Functions to exclude: AD3, SM SMAD4	LO CA	E. L. M. PD. PP. TR. UB () A.E. I. L. P. PP. RB. T. TR. UB (27)
Differentiation of regulat HLA-DRB1air 4	PRDM1 SMAD	DT.PD.PP.RB.T.TASMAD3
Cytostasis of epithelial ce Apply Cancel AD3, SMall 3	<u> </u>	F, FD, FF, RB, T, TR
Activation of CD4+ T-lymping 2.072-09 Inc., new-pitB1, PRDM1all 4		
Formation of abscess 3.55E-09 IL2, SMAD3, SMAD4all 3		
Proliferation of lymphocytes 4.66E-09 IL2, SMAD7, HLA-DRB1all 6		
Formation of skin 4.87E-09 SMAD7, HLA-DRB1, Sall 5	© 2000-2023 QIAGEN. All rights reserved.	
Quantity of mononuclear leu 5.62E-09 IL2, SMAD7, HLA-DRB1all 6	Add To My Dathway	View Shortest Paths + 1 (389) V Paths 1 - 50 V (
Differentiation of T lymphog 1.30E-08 IL2, SMAD7, HLA-DRB1all 5	Add To My Pathway Highlight	view Shortest Patris + 1 (303) V Patris 1 - 30 V
Activation of T lymphocytes 1.71E-08 IL2, HLA-DRB1, SMAD3all 5	Paths Set A Molecules	Node 1 Set B Molecules
Transcription of DNA 3.61E-08 IL2, SMAD7, HLA-DRB1all 6	✓ 1 SMAD3 SM/	AD4 Activation of T lymphocytes
Differentiation of memory T I 4.11E-08 IL2, HLA-DRB1, PRDM1all 3	2 SMAD3 IL2	Activation of T lymphocytes
Cell viability of lymphocytes 5.19E-08 IL2, SMAD3, PRDM1,all 4 Transactivation 5.58E-08 IL2, SMAD7, SMAD3,all 5	3 PRDM1 IL2	Activation of T lymphocytes
Proliferation of tumor cells 1.14E-07 IL2, SMAD7, SMAD3,all 5	✓ 4 HLA-DRB1 IL2	Activation of T lymphocytes
Quantity of T lymphocytes 1.24E-07 IL2, SMAD7, HLA-DRB1all 5	5 HLA-DRB1 TCR	
		nunoglobulin Activation of T lymphocytes
0/355 Reset Apply		Activation of Flymphocytes



🛛 New My Pathway 6

G	🝵 🏫 🗟 Edit: 📝 💭 📾 📾 👘 ᡝ 🕞 🤤 Bu	ild	Overlay Path Desig	ner Pattern Search View:	🗙 < 🦉 🎞 🗉 Zoor	n: 🔄 🙉 Export: 🐼 🎫 📴
	Tool: Grow	~	< New My Pathway 6			
	Molecules & Canonical Pathways Diseases & Functions		> ≫ ♠ ♦ 53 ₱	(¹⁰		
	Grow from selected molecules to selected diseases & functions	0	+	HDA-DRB1		
	Indicate diseases or functions related to Any of the selected molecules		+	V.		
				NN.		
	Consider only functions with names like proliferation*		•	с ө . Е Ф	*	
	Recalculate			Activation	of T lynn tes	
		+ • ×		~ @	C (00) C (00)	
	Proliferation of activated T lyr 1.50E-09 IL2, HLA-DRB1, SMAD3, Proliferation of lymphocytes 4.66E-09 IL2, SMAD7, HLA-DRB1,				L Bhmuroglabulin	
	Proliferation of lymphocytes 4.66E-09 IL2, SMAD7, HLA-DRB1, Proliferation of tumor cells 1.14E-07 IL2, SMAD7, SMAD3,					
	Proliferation of beta islet cell: 3.57E-07 IL2, SMAD7, SMAD3				A.E. I. M. PD. PP. TR. UB A.E. I. L. P. PP. RB. T. TI	R, UB (27)
	Proliferation of B lymphocyte: 4.62E-07 IL2, SMAD7, SMAD3,		•	PRDM1 (S	MAD7, PD, PP, RB, T, TR, SMAD3	
	Proliferation of cancer cells 3.63E-06 IL2, SMAD7, SMAD3,				P. PD. PP. RB. T. TR.	
- 1	Proliferation of hepatocytes 7.03E-06 SMAD7, SMAD3, SMA	all 3				
	Proliferation of Th1 cells 1.94E-05 IL2, HLA-DRB1	all 2				
	Proliferation of T lymphocyte: 2.47E-05 IL2, HLA-DRB1, SMAD4	all 3				
	Proliferation of hematopoieti 2.98E-05 IL2, PRDM1, SMAD4	all 3	© 2000-2023 QIAGEN.	All rights reserved.		
	Proliferation of eye cell lines 4.19E-05 SMAD3, SMAD4	all 2				
	Proliferation of splenocytes 1.25E-04 IL2, SMAD3	all 2	Add To My Pathway	/ Highlight	View Shortest Paths + 1	1 (389) V Paths 1 - 50 V 🔍 🥨
		all 1	Paths	Set A Molecules	Node 1	Set B Molecules
	Proliferation of hepatic stellar 1.57E-02 SMAD3	all 1	1 SM	IAD3	SMAD4	Activation of T lymphocytes
			2 SM	IAD3	IL2	Activation of T lymphocytes
			3 PR	DM1	IL2	Activation of T lymphocytes
				A-DRB1	IL2	Activation of T lymphocytes
				A-DRB1	TCR	Activation of T lymphocytes
S						
	1/14 Reset App	лу	✓ 6 PR	DM1	Immunoglobulin	Activation of T lymphocytes

- \Box >

位

New My Pathway 6

🝵 🏫 🗟 Edit: 📝 💭 🚿 🍙	🗐 ᄼ 🕞 🤤 Build	Overlay Path Designer	Pattern Search View:	🗙 💉 👸 🗊 🗉 Zoor	m: 🕘 📵 Export: 🐼 🎫 📄
Tool: Grow	~	< New My Pathway 6			
		→ 📚 📤	\bigcap		
Molecules & Canonical Pathways Diseases 8	k Functions	4 53 🔶	$\{ \frown \}$		
Grow from selected molecules to selected disease	s & functions	- +	HDA-DRB1		
	-	+	U.		
Indicate diseases or functions related to Any	\sim of the selected molecules				
Consider only					
functions with names like proliferation*					Proliferation of cancer cells
		T T	<u>````</u>	-	
			Activatio	n of T lypp	
Recalculate			(SMAD4	
	+		X		
Diseases and Functions 🔳 👔 p-value	× Molecules T ×		1		and the second se
Proliferation of activated T lyr 1.50E-09	IL2, HLA-DRB1, SMAD3,all 5		/	1-1-1-1	
Proliferation of lymphocytes 4.66E-09	IL2, SMAD7, HLA-DRB1,all 6		/	ILImmunoglopulin	
Proliferation of tumor cells 1.14E-07	IL2, SMAD7, SMAD3,all 5		Q'		
Proliferation of beta islet cell: 3.57E-07	IL2, SMAD7, SMAD3all 3	1	(PRDM1)		
Proliferation of B lymphocyte: 4.62E-07	IL2, SMAD7, SMAD3,all 4			SMAD7 SMAD3	
Proliferation of cancer cells 3.63E-06	IL2, SMAD7, SMAD3,all 4				
Proliferation of hepatocytes 7.03E-06	SMAD7, SMAD3, SMAall 3				
Proliferation of Th1 cells 1.94E-05	IL2, HLA-DRB1all 2				
Proliferation of T lymphocyte: 2.47E-05	IL2, HLA-DRB1, SMAD4all 3				
Proliferation of hematopoieti 2.98E-05	IL2, PRDM1, SMAD4all 3	© 2000-2023 QIAGEN. All r	ights reserved.		
Proliferation of hematopoieti 2.98E-05 Proliferation of eye cell lines 4.19E-05	SMAD3, SMAD4all 2	Add To My Dathway	-	Wiew Chaster Dates	1 (200) V Datha 1 50 V 📿 📿
	SMAD3, SMAD4all 2 IL2, SMAD3all 2	Add To My Dathway	ights reserved. Highlight	•••• View Shortest Paths +	1 (389) V Paths 1 - 50 V 🔍 🤇
Proliferation of eye cell lines 4.19E-05	SMAD3, SMAD4 all 2 IL2, SMAD3 all 2 IL2 all 1	Add To My Dathway	-	View Shortest Paths + Node 1	1 (389) V Paths 1 - 50 V K K
Proliferation of eye cell lines 4.19E-05 Proliferation of splenocytes 1.25E-04	SMAD3, SMAD4all 2 IL2, SMAD3all 2	Add To My Pathway	Highlight Set A Molecules		
Proliferation of eye cell lines4.19E-05Proliferation of splenocytes1.25E-04Proliferation of lymphokine a1.47E-04	SMAD3, SMAD4 all 2 IL2, SMAD3 all 2 IL2 all 1	Add To My Pathway Add To My Pathway Paths Add To SMAD:	Highlight Set A Molecules	Node 1 SMAD4	Set B Molecules Activation of T lymphocytes
Proliferation of eye cell lines4.19E-05Proliferation of splenocytes1.25E-04Proliferation of lymphokine a1.47E-04	SMAD3, SMAD4 all 2 IL2, SMAD3 all 2 IL2 all 1	Add To My Pathway Add To My Pathway Paths Add To My Pathway Add To	Highlight Set A Molecules	Node 1 SMAD4 IL2	Set B Molecules Activation of T lymphocytes Activation of T lymphocytes
Proliferation of eye cell lines4.19E-05Proliferation of splenocytes1.25E-04Proliferation of lymphokine a1.47E-04	SMAD3, SMAD4 all 2 IL2, SMAD3 all 2 IL2 all 1	Add To My Pathway Add To My Pathway Paths I SMAD: 2 SMAD: 3 PRDM	Highlight Set A Molecules	Node 1 SMAD4 IL2 IL2	Set B Molecules Activation of T lymphocytes Activation of T lymphocytes Activation of T lymphocytes
Proliferation of eye cell lines4.19E-05Proliferation of splenocytes1.25E-04Proliferation of lymphokine a1.47E-04	SMAD3, SMAD4 all 2 IL2, SMAD3 all 2 IL2 all 1	Add To My Pathway Add To My Pathway Paths Add To My Pathway Add To	Highlight Set A Molecules 3 3 1 1 RB1	Node 1 SMAD4 IL2 IL2 IL2	Set B Molecules Activation of T lymphocytes Activation of T lymphocytes Activation of T lymphocytes Activation of T lymphocytes
Proliferation of eye cell lines4.19E-05Proliferation of splenocytes1.25E-04Proliferation of lymphokine a1.47E-04	SMAD3, SMAD4 all 2 IL2, SMAD3 all 2 IL2 all 1	Add To My Pathway Add To My Pathway Paths I SMAD: 2 SMAD: 3 PRDM	Highlight Set A Molecules 3 3 1 1 RB1	Node 1 SMAD4 IL2 IL2	Set B Molecules Activation of T lymphocytes Activation of T lymphocytes Activation of T lymphocytes

– 🗆 🗙

位


	My Pathways						
	🔀 New My Pathway 6						
G	📩 🏘 🗟 Edit:	🛛 🕽 💽 👘		🗟 🛛 Build	Overlay	Path Designer	Pa
	Quardaux Piamarkan				< New My	Pathway 6	\frown
	Overlay: Biomarkers			~	> 📚 🛧	(
	Select Biomarker labels fr	rom table to be displayed	on pathway.	0	4 53 6		Δ
	Application /	Disease	# Molecules	Molecule(s)	+	н	DA-DRE
	diagnosis	non-insulin-dependent	1	IL2	- e 1		1
Γ	✓ diagnosis	cystic fibrosis	1	IL2	- ÷		
	diagnos	sarcoidosis	1	IL2			
	diagnosis	sarcopenia	1	IL2			
	diagnosis	Parkinson's disease	1	IL2	- T		
	diagnosis	candidiasis	1	IL2	- L		
	diagnosis	asthma	1	IL2	_		
	disease progression	Parkinson's disease	1	IL2			
	efficacy	HIV infection	1	IL2			
	efficacy	small B-cell lymphocytic	1	IL2			
	efficacy	leukemia	1	IL2		4	γ'
	efficacy	lymphoma	1	IL2		P	RDM1)-
	efficacy	multiple myeloma	1	IL2	:		
	efficacy	obesity	1	IL2	1		
	efficacy	non-Hodgkin lymphoma	1	IL2			
	efficacy	rheumatoid arthritis	1	IL2			
	efficacy	myeloproliferative synd	1	IL2			
	efficacy	acute myeloid leukemia	1	IL2			
	efficacy	myelodysplastic syndro	1	IL2	© 2000-20	23 QIAGEN. All rig	ghts res
	efficacy	marginal zone cell lymp	1	IL2			
	efficacy	follicular lymphoma	1	IL2	Add Io	My Pathway	High
	efficacy	breast cancer	1	IL2		Paths	Se
	prognosis	colorectal cancer	1	SMAD4		1 SMAD3	
	response to therapy	rheumatoid arthritis	1	IL2		2 SMAD3	
	unspecified applic	rheumatoid arthritis	1	SMAD4			
	unspecified applic	gastric mucosa-associat	1	Immunoglobulin		3 PRDM1	
	unspecified applic	ovarian cancer	1	Immunoglobulin		4 HLA-DR	B1
s	unspecified applic	colorectal carcinoma	1	SMAD4		5 HLA-DR	B1

✓ Interactive OFF


 \sim

Mode Label

 \checkmark








🛣 Dataset and Analysis Search						
	ulcerative colitis				Search	0
	Examples: liver, "mouse OR rat", "HeLa N	NOT 3T3", "p?3", "r	ovar*"			
Search Results						
Showing first 1779 results out of 1779 in 29233ms for	r query [ulcerative colitis]			< Libraries > (OmicSoft	> DiseaseLand > HumanDisease > Analyses
Folder Types				1- ulcerativ	ve colitis	(UC) [colon] 10226
• dataset (973)						
analysis (806)				Case/Contr	rol Differ	rences
Projects						
HumanDisease (1348)				Key	Case	Control
• HumanDisease (1346)				response	sensitive	e resistant
Open Add to Overlay Customize Table	e Crea 2023/	/ 2023/ (1/45)	~ « »			1
Name	Matching Term	Туре		Compariso	Contex	
- ulcerative colitis (UC) [colonic mucosa] 26910	exp_meta_data.control.dis		2023/09/30 23:22	Companiso	I CONCEA.	
- ulcerative colitis (UC) [colonic mucosa] 33570	exp_meta_data.case.disea	analysis	2023/09/30 23:22	compariso	ncategory	y Responder vs. Non-Responder
- ulcerative colitis (UC) [colon] 10226	exp_meta_data.control.dis	analysis	2023/09/30 23:22	comparisor		TNFInadequateResponder:Response => NA ->
- ulcerative colitis (UC) [colonic mucosa] 16417	exp_meta_data.compariso	analysis	2023/09/30 23:21	companso		sensitive vs resistant
- ulcerative colitis (UC) [ileal mucosa] 10425	exp_meta_data.case.disea	analysis	2023/09/30 23:21	diseasestat	te	ulcerative colitis (UC)
- ulcerative colitis (UC) [intestinal organoid] 1527	exp_meta_data.compariso	analysis	2023/09/30 23:21	dosage		100 mg
- ulcerative colitis (UC) [colonic mucosa] 17871	exp_meta_data.compariso	analysis	2023/09/30 23:20	organism		human
- ulcerative colitis (UC) [mesenteric adipose tissue] 257	716 exp_meta_data.compariso	analysis	2023/09/30 23:20	platformna	ame	NGS.Illumina.HiSeq2000
- ulcerative colitis (UC) [colonic mucosa] 19885	exp_meta_data.compariso	analysis	2023/09/30 23:20	subjecttrea	atment	etrolizumab
1- ulcerative colitis (UC) [pouch mucosa] 26938	exp_meta_data.compariso	analysis	2023/09/30 23:20	tissue		colon
1- ulcerative colitis (UC) [colonic mucosa] 25110	exp_meta_data.compariso	analysis	2023/09/30 23:19	treatments	status	none
1- ulcerative colitis (UC) [rectum] 8043	exp_meta_data.compariso	analysis	2023/09/30 23:19			
1- ulcerative colitis (UC) [colonic mucosa] 26770	exp_meta_data.compariso	analysis	2023/09/30 23:19	All Experim	ment Met	state
1- ulcerative colitis (UC) [sigmoid colon] 19333	exp_meta_data.control.dis		2023/09/30 23:19	An experim	lent met	adata
1- ulcerative colitis (UC) [colonic mucosa] 29017	exp_meta_data.compariso		2023/09/30 23:18	case.diseas	sestate	ulcerative colitis (UC)
1- ulcerative colitis (UC) [peripheral blood] 14819	exp_meta_data.compariso		2023/09/30 23:18	case.dosag		100 mg
1- ulcerative colitis (UC) [peripheral blood] 154	exp_meta_data.control.dis		2023/09/30 23:17	case.respor		sensitive
				case.sampl		GSM1872906;GSM1872912;GSM1872913;GSM187;

* CCID A 428788 2597..2612 - 個人 - Microsoft Edge |

👪 Dataset and Analysis Search	ulasettina sellitis		Creat	×
	ulcerative colitis	249/2 M/	Search	0
	Examples: liver, "mouse OR rat", "HeLa NOT 3T3", "p?	'3", "ovar*"		
Search Results				
Showing first 1779 results out of 1779 in 29233ms	for query [ulcerative colitis]		Libraries > OmicSoft	> DiseaseLand > HumanDisease > Analyses
Folder Types			1- ulcerative colitis	(UC) [colon] 10226
 <u>dataset (973)</u> analysis (806) 			C	
			Case/Control Differ	ences
Projects			Key Case	Control
HumanDisease (1348)				
Open Add to Overlay Customize Ta		/45) 🗸 🔍 ≫	response sensitive	e resistant
open Add to overlay Customize la			-	
lame	Matching Term Type	√ Creation Da	Comparison Contex	t
- ulcerative colitis (UC) [colonic mucosa] 26910	exp_meta_data.control.dis analysis	2023/09/30 23:22		
- ulcerative colitis (UC) [colonic mucosa] 33570	exp_meta_data.case.disea analysis	2023/09/30 23:22	comparisoncategory	Responder vs. Non-Responder
- ulcerative colitis (UC) [colon] 10226	exp_meta_data.control.dis analysis	2023/09/30 23:22	comparisoncontrast	TNFInadequateResponder:Response => NA -> sensitive vs resistant
- ulcerative colitis (UC) [colonic mucosa] 16417	exp_meta_data.compariso analysis	2023/09/30 23:21	disassastata	ulcerative colitis (UC)
- ulcerative colitis (UC) [ileal mucosa] 10425	exp_meta_data.case.disea analysis	2023/09/30 23:21	diseasestate	100 mg
- ulcerative colitis (UC) [intestinal organoid] 1527	exp_meta_data.compariso analysis	2023/09/30 23:21	dosage organism	human
- ulcerative colitis (UC) [colonic mucosa] 17871	exp_meta_data.compariso analysis	2023/09/30 23:20	platformname	NGS.Illumina.HiSeq2000
- ulcerative colitis (UC) [mesenteric adipose tissue] 2		2023/09/30 23:20	subjecttreatment	etrolizumab
- ulcerative colitis (UC) [colonic mucosa] 19885	exp_meta_data.compariso analysis	2023/09/30 23:20	tissue	colon
- ulcerative colitis (UC) [pouch mucosa] 26938	exp_meta_data.compariso analysis	2023/09/30 23:20	treatmentstatus	none
- ulcerative colitis (UC) [colonic mucosa] 25110	exp_meta_data.compariso analysis	2023/09/30 23:19		
Analyses to overlay	***			
1- ulcerative colitis (UC) [colon] 10226		Up \$	All Experiment Met	adata
		Down ×	case.diseasestate	ulcerative colitis (UC)
		Remove	case.dosage	100 mg
			case.response	sensitive
		Clear All	case.sampleids	GSM1872906;GSM1872912;GSM1872913;GSM1877




Summary: Evaluating your's omics data using IPA


Cytoplasm



_		B	С		
1	geneid	UCvsNormal.Log2FoldChange	UCvsNormal.pva		
2	DDX11L1	-0.1067	0.2878		
3	WASH7P	-0.1883	0.0097		
4	FAM138F	-0.0761	0.4699		
5	OR4F5	0.1474	0.5311		
6	LOC729737	0.4789	0.0017		
7	LOC100133331	0.4789	0.0017		
8	LOC100132062	0.4789	0.0017		
9	OR4F29	0.2495	0.2389		
10	JA429831	0.1215	0.3338		
11	JB137814	-0.674	1.6381E-06		
12	M37726	-1.0551	0.00000576		
13	LINC00115	-0.1666	0.021		
14	LOC643837	0.1025	0.3021		
15	FAM41C	0.2098	0.2554		
16	SAMD11	-0.0552	0.4088		
17	NOC2L	0.3408	1.2575E-08		
18	KLHL17	0.1497	0.0082		
19	PLEKHN1	0.1463	0.0088		
20	C1orf170	-0.1649	0.0085		
1546	TTTY13	-0.3543	0.0003		
1547	RBMY1E	-0.3167	0.016		
1548	PRY2	-0.1792	0.0084		
1549	TTTY6	-0.2051	0.0005		
1550	RBMY1J	-0.3167	0.016		
1551	TTTY5	-0.105	0.0743		
1552	RBMY2FP	-0.5248	0.0939		
1553	RBMY1F	-0.5248	0.0939		
1554	PRY	-0.1792	0.0084		
1555	BPY2	-0.1446	0.0562		
1556	DAZ1	0.0734	0.5811		
1557	DAZ4	0.0734	0.5811		
1558	DAZ2	0.0734	0.5811		
1559	DAZ3	0.0734	0.5811		
1560	CDY1	-0.0319	0.6541		
1561	CSPG4P1Y	-0.0678	0.3043		
1562	GOLGA2P2Y	-0.0872	0.1077		
1563	U6 83	0.21	0.1		




Signaling of TREM1 and association with TLRs





Ulcerative Colitis vs Normal Treatment vs Baseline



- Data upload and analysis setup
- Canonical pathways
- Upstream regulators
- · Diseases and functions
- Comparison analysis







Better Care with Better Knowledge

若有需要進一步的資訊或在使用軟體上遇到問題歡迎聯繫以下窗口: 席佩妤 業務專員 CleoHsi@gga.asia 02-2795 1777 #3019 熊嘉妮 專案主任 ChristineHsiung@gga.asia 02-2795 1777 #3028

Bioinfo@GGA.ASIA